0000897101-16-002321.txt : 20160510 0000897101-16-002321.hdr.sgml : 20160510 20160510165057 ACCESSION NUMBER: 0000897101-16-002321 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 46 CONFORMED PERIOD OF REPORT: 20160331 FILED AS OF DATE: 20160510 DATE AS OF CHANGE: 20160510 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Electromed, Inc. CENTRAL INDEX KEY: 0001488917 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 411732920 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-34839 FILM NUMBER: 161636468 BUSINESS ADDRESS: STREET 1: 500 SIXTH AVENUE NW CITY: NEW PRAGUE STATE: MN ZIP: 56071 BUSINESS PHONE: 952-758-9299 MAIL ADDRESS: STREET 1: 500 SIXTH AVENUE NW CITY: NEW PRAGUE STATE: MN ZIP: 56071 10-Q 1 elmd161673_10q.htm FORM 10-Q FOR THE QUARTER ENDED MARCH 31, 2016

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2016

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________ to ________.

Commission File No.: 001-34839

Electromed, Inc.

(Exact Name of Registrant as Specified in its Charter)

Minnesota		41-1732920
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

500 Sixth Avenue NW New Prague, Minnesota		56071
(Address of principal executive offices)		(Zip Code)

(952) 758-9299

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes þ No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ¨	Accelerated filer ¨
Non-accelerated filer ¨ (Do not check if smaller reporting company)	Smaller reporting company þ

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No þ

There were 8,187,112 shares of Electromed, Inc. common stock, par value $0.01, outstanding as of the close of business on May 6, 2016.

Electromed, Inc.
Index to Quarterly Report on Form 10-Q

		Page

PART I – FINANCIAL INFORMATION

Item 1.	Financial Statements	1
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	9
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	13
Item 4.	Controls and Procedures	14

PART II – OTHER INFORMATION

Item 1.	Legal Proceedings	14
Item 1A.	Risk Factors	14
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	14
Item 3.	Defaults Upon Senior Securities	14
Item 4.	Mine Safety Disclosures	14
Item 5.	Other Information	14
Item 6.	Exhibits	14

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements.

Electromed, Inc.

Condensed Balance Sheets

	March 31, 2016		June 30, 2015
	(Unaudited)
Assets
Current Assets
Cash	$	4,934,112	$	3,598,240
Accounts receivable (net of allowances for doubtful accounts of $45,000)		7,310,731		6,518,816
Inventories		2,325,718		2,072,108
Prepaid expenses and other current assets		442,603		397,833
Income tax receivable		180,785		–
Total current assets		15,193,949		12,586,997
Property and equipment, net		3,388,116		3,635,516
Finite-life intangible assets, net		927,931		999,842
Other assets		160,488		182,699
Deferred income taxes		337,000		–
Total assets	$	20,007,484	$	17,405,054

Liabilities and Shareholders’ Equity
Current Liabilities
Current maturities of long-term debt	$	47,632	$	48,749
Accounts payable		668,796		538,518
Accrued compensation		1,255,054		700,370
Income tax payable		–		122,657
Warranty reserve		670,000		660,000
Other accrued liabilities		246,761		208,983
Total current liabilities		2,888,243		2,279,277
Long-term debt, less current maturities		1,167,166		1,202,446
Total liabilities		4,055,409		3,481,723

Commitments and Contingencies

Equity
Common stock, $0.01 par value; authorized: 13,000,000 shares; 8,187,112 and 8,133,857 issued and outstanding at March 31, 2016 and June 30, 2015, respectively		81,871		81,339
Additional paid-in capital		13,480,253		13,327,320
Retained earnings		2,389,951		514,672
Total shareholders’ equity		15,952,075		13,923,331
Total liabilities and shareholders’ equity	$	20,007,484	$	17,405,054

See Notes to Condensed Financial Statements.

Electromed, Inc.

Condensed Statements of Operations (Unaudited)

	For the Three Months Ended					For the Nine Months Ended
	March 31,					March 31,
	2016			2015		2016			2015

Net revenues	$	6,035,700		$	4,556,977	$	17,298,995		$	14,209,239
Cost of revenues		1,408,716			1,400,252		3,913,984			4,354,339
Gross profit		4,626,984			3,156,725		13,385,011			9,854,900

Operating expenses
Selling, general and administrative		3,806,885			3,020,849		10,631,539			8,714,746
Research and development		84,410			78,292		183,043			237,201
Total operating expenses		3,891,295			3,099,141		10,814,582			8,951,947
Operating income		735,689			57,584		2,570,429			902,953
Interest expense, net of interest income of $4,978, $371 $8,525 and $2,044, respectively		13,064			20,355		51,150			65,484
Net income before income taxes		722,625			37,229		2,519,279			837,469

Income tax expense		(256,000	)		–		(644,000	)		–

Net income	$	466,625		$	37,229	$	1,875,279		$	837,469

Income per share:

Basic	$	.06		$	.00	$	.23		$	.10

Diluted	$	.06		$	.00	$	.23		$	.10

Weighted-average common shares outstanding:
Basic		8,133,857			8,114,252		8,133,857			8,114,252
Diluted		8,287,237			8,166,659		8,215,472			8,131,496

See Notes to Condensed Financial Statements.

Electromed, Inc.

Condensed Statements of Cash Flows (Unaudited)

	Nine Months Ended March 31,
	2016			2015
Cash Flows From Operating Activities
Net income	$	1,875,279		$	837,469
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation		458,850			459,223
Amortization of finite-life intangible assets		91,815			97,931
Amortization of debt issuance costs		13,672			14,546
Share-based compensation expense		153,465			78,596
Deferred taxes		(337,000	)		–
Loss on disposal of property and equipment and intangible assets		46,515			233,116
Changes in operating assets and liabilities:
Accounts receivable		(791,915	)		98,813
Inventories		(220,417	)		(166,368	)
Prepaid expenses and other assets		(22,711	)		(141,854	)
Income tax receivable		(180,785	)		–
Accounts payable and accrued liabilities		583,579			319,717
Net cash provided by operating activities		1,670,347			1,831,189

Cash Flows From Investing Activities
Expenditures for property and equipment		(256,806	)		(379,609	)
Expenditures for finite-life intangible assets		(27,752	)		–
Net cash used in investing activities		(284,558	)		(379,609	)

Cash Flows From Financing Activities
Principal payments on long-term debt including capital lease obligations		(36,397	)		(34,674	)
Payment of deferred financing fees		(13,520	)		(14,797	)
Net cash used in financing activities		(49,917	)		(49,471	)
Net increase in cash		1,335,872			1,402,109
Cash
Beginning of period		3,598,240			1,502,702
End of period	$	4,934,112		$	2,904,811

See Notes to Condensed Financial Statements.

Electromed, Inc.
Notes to Condensed Financial Statements
(Unaudited)

Note 1.

Interim Financial Reporting

Basis of presentation: Electromed, Inc. (the “Company”) develops, manufactures and markets innovative airway clearance products that apply High Frequency Chest Wall Oscillation (“HFCWO”) therapy in pulmonary care for patients of all ages. The Company markets its products in the U.S. to the home health care and institutional markets for use by patients in personal residences, hospitals and clinics. The Company also sells internationally both directly and through distributors. International sales were approximately $591,000 and $599,000 for the nine months ended March 31, 2016 and 2015, respectively. Since its inception, the Company has operated in a single industry segment: developing, manufacturing and marketing medical equipment.

The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles for interim financial statements and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. In the opinion of management, the accompanying unaudited condensed financial statements reflect all adjustments consisting of normal recurring adjustments necessary for a fair presentation of the Company’s financial position and results of operations as required by Regulation S-X. Interim results of operations are not necessarily indicative of the results that may be achieved for the full year. The financial statements and related notes do not include all information and footnotes required by U.S. generally accepted accounting principles for annual reports. This interim report should be read in conjunction with the financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2015 (“fiscal 2015”).

A summary of the Company’s significant accounting policies follows:

Use of estimates: Management uses estimates and assumptions in preparing the condensed financial statements in accordance with accounting principles generally accepted in the U.S. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could vary from the estimates that were used. The Company believes the critical accounting policies that require the most significant assumptions and judgments in the preparation of its condensed financial statements include revenue recognition and the related estimation of selling price adjustments, allowance for doubtful accounts, inventory obsolescence, share-based compensation, income taxes and the warranty reserve.

Net income per common share: Net income is presented on a per share basis for both basic and diluted common shares. Basic net income per common share is computed using the weighted average number of common shares outstanding during the period, excluding any restricted stock awards which have not vested. The diluted net income per common share calculation includes outstanding restricted stock grants and assumes that all stock options were exercised and converted into common stock at the beginning of the period, unless their effect would be anti-dilutive. Common stock equivalents excluded from the calculation of diluted earnings per share because their impact was anti-dilutive was 159,000 and 163,500 for the three and nine months ended March 31, 2016, respectively, and 539,900 and 609,900 for the three and nine months ended March 31, 2015, respectively.

New accounting pronouncements: In May 2014, the Financial Accounting Standards Board (“FASB”) issued guidance creating Accounting Standards Codification (“ASC”) Section 606, “Revenue from Contracts with Customers”. The new section will replace ASC Section 605, “Revenue Recognition” and creates modifications to various other revenue accounting standards for specialized transactions and industries. The section is intended to conform revenue accounting principles with a concurrently issued International Financial Reporting Standards with previously differing treatment between U.S. practice and that of much of the rest of the world, as well as to enhance disclosures related to disaggregated revenue information. Entities will have the option to apply the standard retrospectively to all prior periods presented, or to apply it retrospectively only to contracts existing at the effective date, with the cumulative effect of the standard recorded as an adjustment to beginning retained earnings. The updated guidance will be effective for the Company’s annual reporting period beginning with our fiscal year ending June 30, 2019, and interim periods within that year. The Company is evaluating the impact of this standard on its financial statements.

In April 2015, FASB issued Accounting Standards Update (“ASU”) 2015-03, “Simplifying the Presentation of Debt Issuance Costs.” This standard, which will become effective July 1, 2016 for the Company, requires that debt issuance costs be presented as a direct deduction from the carrying amount of long-term debt on the balance sheet. The new guidance aligns the presentation of debt issuance costs with debt discounts and premiums. The standard is to be applied retrospectively to all prior periods presented. As of March 31, 2016, the Company had approximately $21,000 of unamortized debt issuance costs recorded in other non-current assets on its balance sheet.

In July 2015, FASB issued ASU 2015-11, “Inventory (Topic 330) Related to Simplifying the Measurement of Inventory,” which applies to all inventory except that which is measured using last-in, first-out (“LIFO”) or the retail inventory method. Inventory measured using first-in, first-out (“FIFO”) or average cost is within the scope of the new guidance and should be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable cost of completion, disposal, and transportation. Subsequent measurement is unchanged for inventory measured using LIFO or the retail inventory method. The amendments will be effective for public business entities for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The new guidance should be applied prospectively, and earlier application is permitted as of the beginning of an interim or annual reporting period. The Company is evaluating the impact of the standard on its financial statements.

In November 2015, FASB issued ASU 2015-17, “Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes.” This standard requires that deferred tax assets and liabilities (“DTAs” and “DTLs”) be classified as noncurrent on the balance sheet rather than being separated into current and noncurrent. The ASU simplifies the current guidance (ASC 740-10-45-4), which requires entities to separately present DTAs and DTLs as current and noncurrent in a classified balance sheet. ASU 2015-17 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. Early adoption is permitted and the standard may be applied either retrospectively or on a prospective basis to all deferred tax assets and liabilities. The Company has elected to adopt ASU 2015-17 early and it has been applied to its second quarter of fiscal 2016 on a prospective basis.

In February 2016, FASB issued ASU 2016-02, “Leases.” This standard requires the recognition of all lease transactions with terms in excess of 12 months on the balance sheet as a lease liability and a right-of-use asset (as defined in the standard). ASU 2016-02 will be effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with earlier application permitted. Upon adoption, the lessee will apply the new standard retrospectively to all periods presented or retrospectively using a cumulative effect adjustment in the year of adoption. The Company is currently assessing the effect that ASU 2016-02 will have on its financial statements.

In March 2016, FASB issued ASU 2016-09, “Compensation–Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting”, which reduces complexity in accounting standards related to share-based payment transactions, including, among others, (1) accounting for income taxes, (2) classification of excess tax benefits on the statement of cash flow, (3) forfeitures, and (4) statutory tax withholding requirements. The ASU will be effective for annual reporting periods beginning on or after December 15, 2016, and interim periods within those annual periods, with earlier application permitted. The Company is evaluating the impact of the standard on its financial statements.

Reclassifications: Certain items in the financial statements for fiscal 2015 have been reclassified to be consistent with the classifications adopted for the Company’s fiscal year ending June 30, 2016. The fiscal 2015 reclassifications had no impact on previously reported net income or equity.

Note 2.

Inventories

The components of inventory were approximately as follows:

	March 31, 2016			June 30, 2015
Parts inventory	$	1,630,000		$	1,527,000
Work in process		128,000			245,000
Finished goods		723,000			440,000
Less: Reserve for obsolescence		(155,000	)		(140,000	)
Total	$	2,326,000		$	2,072,000

Note 3.

Finite-life Intangible Assets

The carrying value of patents and trademarks includes the original cost of obtaining the patents, periodic renewal fees, and other costs associated with maintaining and defending patent and trademark rights. Patents and trademarks are amortized over their estimated useful lives, generally 15 and 12 years, respectively. During the nine months ended March 31, 2016 and the year ended June 30, 2015, the Company abandoned certain domestic and foreign patents with net values of approximately $8,000 and $32,000, respectively, which was included as an expense in selling, general and administrative expense on the statements of operations. The patents covered technology that management considered outdated and was no longer in use. Accumulated amortization was $789,000 and $698,000 at March 31, 2016 and June 30, 2015, respectively.

The activity and balances of finite-life intangible assets were approximately as follows:

	Nine Months Ended March 31, 2016			Fiscal Year Ended June 30, 2015
Balance, beginning	$	1,000,000		$	1,039,000
Additions		28,000			116,000
Abandonments		(8,000	)		(32,000	)
Amortization expense		(92,000	)		(123,000	)
Balance, ending	$	928,000		$	1,000,000

Note 4.

Warranty Liability

The Company provides a lifetime warranty on its products to the prescribed patient for sales within the U.S. and a three-year warranty for all institutional sales and sales to individuals outside the U.S. The Company estimates the costs that may be incurred under its warranty and records a liability in the amount of such costs at the time the product is shipped. Factors that affect the Company’s warranty liability include the number of units shipped, historical and anticipated rates of warranty claims, the product’s useful life and cost per claim. The Company periodically assesses the adequacy of its recorded warranty liability and adjusts the amounts as necessary.

Changes in the Company’s warranty liability were approximately as follows:

	Nine Months Ended March 31, 2016			Fiscal Year Ended June 30, 2015
Beginning warranty reserve	$	660,000		$	700,000
Accrual for products sold		130,000			139,000
Expenditures and costs incurred for warranty claims		(120,000	)		(179,000	)
Ending warranty reserve	$	670,000		$	660,000

Note 5.

Income Taxes

On a quarterly basis, the Company estimates its effective tax rate for the full fiscal year and records a quarterly income tax provision based on the anticipated rate. As the year progresses, the Company refines its estimate based on the facts and circumstances by each tax jurisdiction. Income tax expense was estimated at approximately $644,000 and the effective tax rate was 25.5% for the nine months ended March 31, 2016. Estimated income tax expense, during the nine months ended March 31, 2016, includes a current tax expense of $938,000 and a discrete tax benefit of $294,000 due primarily to the Company’s release of the full valuation allowance against all of its net U.S. federal and state deferred tax assets.

For the nine months ended March 31, 2015, the Company recorded zero tax expense. As income was earned the Company’s net operating loss carryforwards were applied to reduce taxable income to zero. Accordingly, the application of the net operating losses to reduce taxable income reduced the Company’s gross deferred tax assets. This reduction of the Company’s gross deferred tax assets caused a corresponding decrease in the respective valuation allowance. For the three and nine months ended March 31, 2015, the Company recorded an income tax expense of zero and the decrease in its deferred tax assets and the corresponding reduction in its deferred tax asset valuation allowance was approximately $27,000 and $358,000, respectively.

During the fiscal year ended June 30, 2014, the Company recorded a full valuation allowance against all of its net U.S. federal and state deferred tax assets. The Company assesses whether a valuation allowance should be established against its deferred tax assets based on consideration of all available evidence, using a “more likely than not” standard. In assessing the need for a valuation allowance, the Company considered both positive and negative evidence related to the likelihood of realization of deferred tax assets. In making such assessments, more weight was given to evidence that could be objectively verified. Future sources of taxable income considered in determining the amount of recorded valuation allowance include:

Taxable income in prior carryback years, if carryback is permitted under the tax law;

Future reversals of existing taxable temporary differences, excluding those related to indefinite-lived intangible assets;

Tax planning strategies; and

Future taxable income exclusive of reversing temporary differences and carryforwards.

On a quarterly basis, the Company evaluates all positive and negative evidence, as described above, in determining if the valuation allowance is fairly stated. At December 31, 2015, the Company determined that, based on the profitability it had achieved, historical cumulative profits and estimates of future income, there was sufficient positive evidence to conclude that the likelihood of realization of deferred tax assets outweigh the negative evidence. The full valuation allowance was released, which resulted in the recognition of $288,000 in net deferred tax assets and a decrease in income tax expense for the nine month period ended March 31, 2016.

Note 6.

Financing Arrangements

The Company has a credit facility that provides for a revolving line of credit and a term loan. Effective December 18, 2015, the Company renewed its $2,500,000 revolving line of credit. There was no outstanding principal balance on the line of credit as of March 31, 2016 or June 30, 2015. Interest on borrowings under the line of credit, if any, would accrue at the prime rate (3.50% at March 31, 2016) and is payable monthly. The amount eligible for borrowing on the line of credit is limited to the lesser of $2,500,000 or 57.00% of eligible accounts receivable and the line of credit expires on December 18, 2016, if not renewed. At March 31, 2016, the maximum $2,500,000 was eligible for borrowing. The line of credit is secured by a security interest in substantially all of the tangible and intangible assets of the Company.

In connection with the credit facility, the Company also has a term loan, which had an outstanding principal balance of approximately $1,210,000 at March 31, 2016. The term loan bears interest at 5.00%, with monthly payments of principal and interest of approximately $8,600 and a final payment of principal and interest of approximately $1,090,000 due on the maturity date of December 18, 2018. Payment obligations under the term loan are secured by a mortgage on the Company’s real property.

The documents governing the line of credit and term loan contain certain financial and nonfinancial covenants that include a minimum tangible net worth covenant of not less than $10,125,000 and restrictions on the Company’s ability to incur certain additional indebtedness or pay dividends.

Note 7.

Stock-Based Compensation

The Company recorded $153,000, and $79,000 of compensation expense related to current and past grants of stock options and restricted stock for the nine months ended March 31, 2016 and 2015, respectively. This expense is included in selling, general and administrative expense. As of March 31, 2016, approximately $184,000 of total unrecognized compensation expense related to non-vested equity awards is expected to be recognized over a weighted average period of approximately 1.1 years.

Stock Options

The Company issued 163,500 stock options pursuant to its 2014 Stock Compensation Plan during the nine months ended March 31, 2016. Stock option transactions during the nine months ended March 31, 2016 are summarized as follows:

	Number of Shares			Weighted Average Exercise Price
Outstanding at June 30, 2015		450,800			$2.80
Granted		163,500			$2.05
Exercised		–			–
Cancelled or Forfeited		(14,500	)		$1.80
Outstanding at March 31, 2016		599,800			$2.62

The intrinsic value of an option is the amount by which the fair value of the underlying stock exceeds its exercise price. At March 31, 2016, the weighted average remaining contractual term for all outstanding stock options was 5.63 years and their aggregate intrinsic value was approximately $693,000. During the nine months ended March 31, 2016, 190,000 options issued in conjunction with the Company’s 2010 initial public offering and 44,100 warrants issued with convertible debt, prior to 2010, expired. Outstanding at March 31, 2016 were the 599,800 employee stock options, of which approximately 389,000 are exercisable and have an aggregate intrinsic value of approximately $220,000.

Restricted Stock

The Company’s 2014 Stock Compensation Plan permits its Compensation Committee to grant other stock-based awards. The Company makes restricted stock grants to key employees and non-employee directors that vest over six months to three years.

During the nine months ended March 31, 2016, the Company issued restricted stock awards to employees totaling 30,000 shares of common stock, with a vesting term of one to three years and a fair value of $1.80 per share, and to directors totaling 23,255 shares of common stock, with a vesting term of six months and a fair value of $2.15 per share. Restricted stock transactions during the nine months ended March 31, 2016 are summarized as follows:

	Number of Shares		Weighted Average Grant Date Fair Value
Unvested shares at June 30, 2015		–		–
Granted		53,255		$1.95
Vested		–		–
Forfeited		–		–
Unvested at March 31, 2016		53,255		$1.95

Note 8.

Commitments and Contingencies

The Company is occasionally involved in claims and disputes arising in the ordinary course of business. The Company insures its business risks where possible to mitigate the financial impact of individual claims, and establishes reserves for an estimate of any probable cost of settlement or other disposition.

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our condensed financial statements and related notes thereto included in Item 1 of Part I of this Quarterly Report on Form 10-Q and the audited financial statements, related notes thereto and Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2015, or “fiscal 2015.”

Overview

Electromed, Inc. (“we,” “our,” “us,” or the “Company”) develops and provides innovative airway clearance products applying High Frequency Chest Wall Oscillation (“HFCWO”) technologies in pulmonary care for patients of all ages.

We manufacture, market and sell products that provide HFCWO, including the SmartVest^®Airway Clearance System (“SmartVest System”) that includes our newest generation SmartVest SQL^® and previous generation SV2100, and related products, to patients with compromised pulmonary function. The SmartVest SQL is smaller, quieter and lighter than our previous product, with enhanced programmability and ease of use. Our products are sold in both the home health care market and the institutional market for use by patients in hospitals, which we refer to as “institutional sales.” The SmartVest SQL has been sold in the domestic home care market since the quarter ended March 31, 2014. In the fourth quarter of fiscal 2015, we launched the SmartVest SQL into the institutional and certain international markets. Since 2000, we have marketed the SmartVest System and its predecessor products to patients suffering from cystic fibrosis, bronchiectasis and repeated episodes of pneumonia. Additionally, we offer our products to a patient population that includes neuromuscular disorders such as cerebral palsy, muscular dystrophies, amyotrophic lateral sclerosis (“ALS”), the combination of emphysema and chronic bronchitis commonly known as chronic obstructive pulmonary disease (“COPD”), and patients with post-surgical complications or who are ventilator dependent or have other conditions involving excess secretion and impaired mucus transport.

The SmartVest System is often eligible for reimbursement from major private insurance providers, health maintenance organizations, or “HMOs”, state Medicaid systems, and the federal Medicare system, which is an important consideration for patients considering an HFCWO course of therapy. For domestic sales, the SmartVest System may be reimbursed under the Medicare-assigned billing code for HFCWO devices if the patient has cystic fibrosis, bronchiectasis (including chronic bronchitis or COPD that has resulted in a diagnosis of bronchiectasis), or any one of certain enumerated neuro-muscular diseases, and can demonstrate that another less expensive physical or mechanical treatment did not adequately mobilize retained secretions. Private payers consider a variety of sources, including Medicare, as guidelines in setting their coverage policies and payment amounts.

Critical Accounting Policies and Estimates

The critical accounting policies used in the preparation of the condensed financial statements as of March 31, 2016 are consistent with the critical accounting policies and estimates disclosed in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and Note 1 to our audited financial statements, included in Part II, Item 8, of our Annual Report on Form 10-K for fiscal 2015.

Some of our accounting policies require us to exercise significant judgment in selecting the appropriate assumptions for calculating financial statements. Such judgments are subject to an inherent degree of uncertainty. These judgments are based upon our historical experience, known trends in our industry, terms of existing contracts and other information from outside sources, as appropriate. We believe the critical accounting policies that require the most significant assumptions and judgments in the preparation of our financial statements include: revenue recognition and the estimation of selling price adjustments, allowance for doubtful accounts, inventory obsolescence, share-based compensation, income taxes and warranty liability.

Results of Operations

Revenues

Revenue for the three- and nine- months ended March 31, 2016 and 2015 are summarized in the table below (dollar amounts in thousands).

	Three Months Ended March 31,									Nine Months Ended March 31,
	2016		2015		Increase / (Decrease)					2016		2015		Increase / (Decrease)
Total Revenue	$	6,036	$	4,557	$	1,479		32.5	%	$	17,299	$	14,209	$	3,090		21.7	%
Home Care Revenue		5,356		3,893		1,463		37.6	%		15,343		12,417		2,926		23.6	%
Institutional Revenue		440		503		(63	)	(12.5	%)		1,365		1,193		172		14.4	%
International Revenue		240		161		79		49.1	%		591		599		(8	)	(1.3	%)

Home Care Revenue. Home care revenue, for the three months ended March 31, 2016, was approximately $5,356,000, an increase of approximately $1,463,000, or 37.6%, compared to the same period in fiscal 2015. For the nine months ended March 31, 2016, home care revenue was approximately $15,343,000, an increase of approximately $2,926,000, or 23.6%, compared to the same period in fiscal 2015. The increase in revenue was primarily due to an increase in approvals from third-party payers as of result of continued improvements in our reimbursement operations, including new third-party payer contracts and process improvements leading to greater referral to approval percentage, faster approval cycle times and higher average selling price. These improvements were also aided by approximately $250,000 of additional revenue during the second quarter of fiscal 2016, compared to the same period in the prior year. This additional revenue came from processing a backlog of referrals from fiscal 2015 in a state where we obtained our home medical equipment license early during the quarter ended September 2015, because we temporarily were without a license during fiscal 2015 after the state’s licensing body imposed an instate presence requirement.

Institutional Revenue. Institutional revenue, for the three months ended March 31, 2016, was approximately $440,000 a decrease of approximately $63,000, or 12.5%, compared to the same period in fiscal 2015. For the nine months ended March 31, 2016, institutional revenue was approximately $1,365,000, an increase of approximately $172,000, or 14.4%, compared to the same period in fiscal 2015. The decrease in revenue for the three months ended March 31, 2016 was primarily due to fewer units sold compared to the same period in the prior year. The increase in institutional revenue for the nine months ended March 31, 2016 was primarily due to selling more units compared to the same period in the prior year. Institutional revenue includes sales to distributors, group purchasing organization (“GPO”) members and other institutions.

International Revenue. International revenue, for the three months ended March 31, 2016, was approximately $240,000, representing an increase of approximately $79,000 or 49.1%, compared to the same period in fiscal 2015. For the nine months ended March 31, 2016, international revenue was approximately $591,000, a decrease of approximately $8,000 or 1.3% from the same period in fiscal 2015. International sales are affected by the timing of distributor purchases that can cause significant fluctuations in reported revenue on a quarterly basis.

Gross profit

Gross profit increased to approximately $4,627,000, or 76.7% of net revenues, for the three months ended March 31, 2016, from approximately $3,157,000, or 69.3% of net revenues, in the same period in fiscal 2015. Gross profit increased to approximately $13,385,000, or 77.4% of net revenues, for the nine months ended March 31, 2016, from approximately $9,855,000, or 69.4% of net revenues, in the same period in fiscal 2015. The increases in gross profit percent resulted from increases in domestic home care revenues, with a higher approval percentage on devices shipped, higher average selling price per unit, and a decrease in our manufacturing costs of the SmartVest SQL as compared to the prior fiscal year.

Operating expenses

Selling, general and administrative expenses. Selling, general and administrative (“SG&A”) expenses were approximately $3,807,000 and $10,632,000 for the three and nine months ended March 31, 2016, respectively, representing an increase of approximately $786,000 and $1,917,000, or 26.0% and 22.0%, compared to the same periods in the prior year. Payroll and compensation-related expenses were approximately $2,206,000 and $6,071,000 for the three and nine months ended March 31, 2016, respectively, representing an increase of approximately $545,000 and $1,260,000, or 32.8% and 26.2%, compared to the same periods in the prior year. The increase in fiscal 2016 was due to additional bonuses and commissions on higher revenue and profitability, annual salary increases, higher share-based equity compensation expense and having additional employees in our sales and reimbursement departments.

Professional fees for the three and nine months ended March 31, 2016 were approximately $379,000 and $946,000 respectively, an increase of approximately $154,000 and $273,000, or 68.4% and 40.6%, compared to the same periods in the prior year. These fees are for services related to legal costs, reporting requirements, information technology (“IT”) security and backup, and printing and other shareowner services. The increase in professional fees was primarily due to an increase in consulting fees associated with IT improvements and outsourcing certain IT services, recruiting fees and training.

Travel, meals and entertainment expenses were approximately $384,000 and $1,076,000 for the three and nine months ended March 31, 2016, respectively, representing an increase of approximately $96,000 and $222,000, or 33.3% and 26.0% compared to the same periods in the prior year. The increase was due primarily to additional sales personnel and an overall increase in travel expense per salesperson.

In addition, SG&A expenses included medical device excise tax of approximately $0 and $132,000 for the three and nine months ended March 31, 2016, representing a decrease of approximately $60,000 and $37,000, respectively, compared to the same periods in the prior year. Beginning with the third quarter of fiscal 2016, we realized a positive impact to operating profit with the recent Consolidated Appropriations Act, 2016 that included a two-year moratorium on the medical device excise tax that began January 1, 2016.

Research and development expenses. Research and development expenses were approximately $84,000 and $183,000 for the three and nine months ended March 31, 2016, respectively, representing an increase of approximately $6,000, a decrease of approximately $54,000 for the three and nine months ended March 31, 2016, compared to the same periods in the prior year. Research and development expenses for the three and nine months ended March 31, 2016 were 1.4% and 1.1% of revenue, respectively, compared to 1.7% of revenue for the three and nine month periods in the prior year. Research and development costs remained below our expected spend as a percentage of revenue, reflecting our completion of the majority of our SmartVest SQL manufacturing cost reduction projects. As a percentage of sales, we expect to increase spending on research and development expenses over the next twelve months with engineering resources focusing on product enhancements and other market opportunities. Certain expenses related to our innovation investments are not always captured in research and development expenses. These expenses may be included in cost of sales as in the case of depreciation of tooling or in SG&A in the case of professional fees or higher labor expense, as we improve our internal processes or add to our customer service.

Interest expense

Interest expense, net, was approximately $13,000 and $51,000, for the three and nine months ended March 31, 2016 compared to $20,000 and $65,000, respectively, in the same periods in the prior year due to lower levels of long-term debt and increased interest income.

Income tax expense

Income tax expense was estimated at approximately $256,000 and $644,000 and the effective tax rates were 35.4% and 25.5%, respectively, for the three and nine months ended March 31, 2016. For the three and nine months ended March 31, 2015, we recorded zero tax expense. Income tax expense during the three and nine months ended March 31, 2016 includes a current tax expense of $256,000 and $938,000. The nine months ended March 31, 2016 also includes a discrete tax benefit of $294,000 due primarily to our release of the full valuation allowance against all of its net U.S. federal and state deferred tax assets. During the three and nine months ended March 31, 2015, as income was earned our net operating loss carryforwards were applied to reduce taxable income. Accordingly, the application of the net operating losses to reduce taxable income reduced our gross deferred tax assets. This reduction of our gross deferred tax assets caused a corresponding decrease in the respective valuation allowance. For the three and nine months ended March 31, 2015, we recorded an income tax expense of zero and the decrease in its deferred tax assets and corresponding reduction in its deferred tax asset valuation allowance was approximately $176,000 and $331,000, respectively.

Net income

Net income for the three and nine months ended March 31, 2016 was approximately $467,000 and $1,875,000, respectively, compared to net income of approximately $37,000 and $837,000 for the same periods in the prior year. The increases in net income were the result of increased revenue and reductions in manufacturing costs year over year. The increase also was affected by releasing the allowance on our net deferred tax assets, which decreased income tax expense by approximately $288,000 during the nine month period ended March 31, 2016.

Liquidity and Capital Resources

Cash Flows and Sources of Liquidity

Cash Flows from Operating Activities

For the nine months ended March 31, 2016, net cash provided by operating activities was approximately $1,670,000. Cash flows provided by operating activities consisted of approximately $1,875,000 in net income, net non-cash expenses of approximately $427,000, an increase in accounts payable and accrued liabilities of approximately $584,000, offset by increases in accounts receivable, inventories prepaid expenses and other assets and income tax receivable of approximately $792,000, $220,000, $22,000 and $181,000, respectively.

For the nine months ended March 31, 2015, net cash provided by operating activities was approximately $1,831,000. Cash flows provided by operations consisted of approximately $837,000 in net income, adjusted for non-cash expenses of approximately $883,000 and a decrease in accounts receivable of $99,000, offset by increases in inventory and prepaid expenses and other assets of $166,000 and $142,000, respectively. In addition, accounts payable and accrued liabilities increased approximately $320,000.

Cash Flows from Investing Activities

For the nine months ended March 31, 2016, cash used in investing activities was approximately $285,000. Cash used in investing activities consisted of approximately $257,000 in expenditures for property and equipment and $28,000 in payments for patent costs.

For the nine months ended March 31, 2015, cash used in investing activities was approximately $380,000 for purchases of property and equipment.

Cash Flows from Financing Activities

For the nine months ended March 31, 2016, cash used in financing activities was approximately $50,000, which consisted of principal payments on long-term debt of $36,000, and payments of deferred financing fees of $14,000.

For the nine months ended March 31, 2015, cash used in financing activities was approximately $50,000, which consisted of principal payments on long-term debt of $35,000, and payments of deferred financing fees of $15,000.

Adequacy of Capital Resources

Our primary working capital requirements relate to adding employees to our sales force and support functions, continuing research and development efforts, and supporting general corporate needs, including financing equipment purchases and other capital expenditures incurred in the ordinary course of business. Based on our current operational performance, we believe our working capital of approximately $12,300,000 as of March 31, 2016 and available borrowings under our existing credit facility will provide adequate liquidity for the next year.

Effective December 18, 2015, we renewed our credit facility, which provides us with a revolving line of credit and a term loan. Interest on borrowings on the line of credit accrues at the prime rate and is payable monthly. The amount eligible for borrowing on the line of credit is limited to the lesser of $2,500,000 or 57.00% of eligible accounts receivable, and the line of credit expires on December 18, 2016, if not renewed. At March 31, 2016, the maximum $2,500,000 was available under the credit facility and the applicable interest rate (the prime rate) was 3.50%. Payment obligations under the line of credit are secured by a security interest in substantially all of our tangible and intangible assets.

The term loan had an outstanding principal balance of approximately $1,210,000 and $1,241,000 at March 31, 2016 and June 30, 2015, respectively. The term loan bears interest at 5.00%, with monthly payments of principal and interest of approximately $8,600 and a final payment of principal and interest of approximately $1,090,000 due on the maturity date of December 18, 2018. Payment obligations under the term loan are secured by a mortgage on our real property.

The documents governing our line of credit and term loan contain certain financial and nonfinancial covenants that include a minimum tangible net worth of not less than $10,125,000 and restrictions on our ability to incur certain additional indebtedness or pay dividends. We were in compliance with these covenants as of March 31, 2016.

Any failure to comply with these covenants in the future may result in an event of default, which if not cured or waived, could result in the lender accelerating the maturity of our indebtedness, preventing access to additional funds under the line of credit and/or term loan, requiring prepayment of outstanding indebtedness under either arrangement, or refusing to renew the line of credit. If the maturity of the indebtedness is accelerated or the line of credit is not renewed, sufficient cash resources to satisfy the debt obligations may not be available and we may not be able to continue operations as planned. The indebtedness under the line of credit and term loan are secured by a security interest in substantially all of our tangible and intangible assets and a mortgage on our real property, respectively. If we are unable to repay such indebtedness, the lender could foreclose on these assets.

For the first nine months of fiscal 2016 and 2015, we spent approximately $257,000 and $380,000, respectively, on property and equipment. We currently expect to finance planned equipment purchases with cash flows from operations or borrowings under our credit facility. We may need to incur additional debt if we have an unforeseen need for additional capital equipment or if our operating performance does not generate adequate cash flows.

Off-Balance Sheet Arrangements

As of March 31, 2016, we had no off-balance sheet arrangements.

Cautionary Note Regarding Forward-Looking Statements

The foregoing discussion and other statements in this report contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act). Words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “may,” “should,” “will”, “would,” and similar expressions, including the negative of these terms, are intended to identify forward-looking statements but are not the exclusive means of identifying such statements. Forward-looking statements include, but are not limited to, statements regarding the following: our expectations regarding international markets and associated regulations and their impact on our sales; our expectations regarding long-term margins; our expectations regarding the expansion of the market for the SmartVest SQL; our expectations regarding research and development expenses; our expectations regarding sales growth, future efficiencies and profitability with the increase in our sales force; our expectations regarding capital expenditures; our expectations regarding our deferred tax assets; and our beliefs regarding the sufficiency of working capital and our ability and intention with regard to future financing. Although we believe these forward-looking statements are reasonable, they involve risks and uncertainties that may cause actual results to differ materially from those projected by such statements. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results or our industry’s actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements.

Factors that could cause actual results to differ from those discussed in the forward-looking statements include, but are not limited to: the competitive nature of our market; the risks associated with expansion into international markets; changes to Medicare, Medicaid, or private insurance reimbursement policies; changes to health care laws; changes affecting the medical device industry; our need to maintain regulatory compliance and to gain future regulatory approvals and clearances; our ability to protect and expand our intellectual property portfolio; our ability to renew our line of credit or obtain additional financing as necessary; and general economic and business conditions. This list of factors is not exhaustive, however, and these or other factors, many of which are outside of our control, could have a material adverse effect on us and our results of operations. Therefore, you should consider these factors with caution and form your own critical and independent conclusions about the likely effect of these factors on our future performance. Forward-looking statements speak only as of the date on which the statements are made, and we undertake no obligation to update any forward-looking statement for any reason, even if new information becomes available or other events occur in the future. You should carefully review the disclosures and the identified risks described in this and other documents we file from time to time with the U.S. Securities and Exchange Commission.

Item 3.

Quantitative and Qualitative Disclosures About Market Risk.

As a smaller reporting company, we are not required to provide disclosure pursuant to this item.

Item 4.

Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our principal executive officer and principal financial officer evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Exchange Act, as of the end of the period subject to this Quarterly Report on Form 10-Q. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of the date of such evaluation to provide reasonable assurance that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified by the U.S. Securities and Exchange Commission’s rules and forms.

Changes to Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the three months ended March 31, 2016 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1.

Legal Proceedings.

Occasionally, we may be party to legal actions, proceedings, or claims in the ordinary course of business, including claims based on assertions of patent and trademark infringement. Corresponding costs are accrued when it is probable that loss will be incurred and the amount can be precisely or reasonably estimated. We are not aware of any undisclosed actual or threatened litigation that would have a material adverse effect on our financial condition or results of operations.

Item 1A.

Risk Factors.

As a smaller reporting company, we are not required to provide disclosure pursuant to this item.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3.

Defaults Upon Senior Securities.

None.

Item 4.

Mine Safety Disclosures.

None.

Item 5.

Other Information.

None.

Item 6.

Exhibits.

The Exhibit Index following the signature page to this report is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


		ELECTROMED, INC.

Date:	May 10, 2016	/s/ Kathleen S. Skarvan
		Kathleen S. Skarvan, President and Chief Executive Officer
		(duly authorized officer)

Date:	May 10, 2016	/s/ Jeremy T. Brock
		Jeremy T. Brock, Chief Financial Officer
		(principal financial officer and principal accounting officer)

EXHIBIT INDEX

Electromed, Inc.

Form 10-Q

Unless otherwise indicated, all documents incorporated into this Quarterly Report on Form 10-Q by reference to a document filed with the SEC pursuant to the Exchange Act are located under SEC file number 001-34839.

Exhibit Number	Description	Method of Filing
3.1	Composite Articles of Incorporation, as amended through November 8, 2010 (incorporated by reference to Exhibit 3.1 to Annual Report on Form 10-K for the fiscal year ended June 30, 2015)	Incorporated by Reference

3.2	Composite Bylaws, as amended through June 30, 2012 (incorporated by reference to Exhibit 3.2 to Annual Report on Form 10-K for the fiscal year ended June 30, 2015)	Incorporated by Reference

31.1	Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	Filed Electronically

31.2	Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	Filed Electronically

32.1	Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	Filed Electronically

32.2	Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	Filed Electronically

101	Financial statements from the Quarterly Report on Form 10-Q for the periods ended March 31, 2016, formatted in XBRL: (i) Condensed Balance Sheets, (ii) Condensed Statements of Income, (iii) Condensed Statements of Cash Flows, and (iv) Notes to Condensed Financial Statements	Filed Electronically

EX-31.1 2 elmd161673_ex31-1.htm CERTIFICATION OF CEO PURSUANT TO SECTION 302

Exhibit 31.1

Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Kathleen S. Skarvan, certify that:

I have reviewed this report on Form 10-Q of Electromed, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 10, 2016	/s/ Kathleen S. Skarvan
	Kathleen S. Skarvan
	President and Chief Executive Officer

EX-31.2 3 elmd161673_ex31-2.htm CERTIFICATION OF CFO PURSUANT TO SECTION 302

Exhibit 31.2

Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Jeremy T. Brock, certify that:

I have reviewed this report on Form 10-Q of Electromed, Inc.;

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 10, 2016	/s/ Jeremy T. Brock
	Jeremy T. Brock
	Chief Financial Officer

EX-32.1 4 elmd161673_ex32-1.htm CERTIFICATION OF CEO PURSUANT TO SECTION 906

Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with this Quarterly Report of Electromed, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2016, as filed with the Securities and Exchange Commission (the “Report”), I, Kathleen S. Skarvan, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 10, 2016	/s/ Kathleen S. Skarvan
	Kathleen S. Skarvan
	President and Chief Executive Officer

EX-32.2 5 elmd161673_ex32-2.htm CERTIFICATION OF CFO PURSUANT TO SECTION 906

Exhibit 32.2

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with this Quarterly Report of Electromed, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2016, as filed with the Securities and Exchange Commission (the “Report”), I, Jeremy T. Brock, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 10, 2016	/s/ Jeremy T. Brock
	Jeremy T. Brock
	Chief Financial Officer

EX-101.INS 6 elmd-20160331.xml XBRL INSTANCE FILE 0001488917 2015-07-01 2016-03-31 0001488917 2016-05-06 0001488917 2014-07-01 2015-06-30 0001488917 elmd:VentureBankMember us-gaap:RevolvingCreditFacilityMember 2016-03-31 0001488917 us-gaap:EmployeeStockOptionMember 2015-06-30 0001488917 elmd:WarrantySalesMember 2015-07-01 2016-03-31 0001488917 2015-06-30 0001488917 2016-03-31 0001488917 2014-07-01 2015-03-31 0001488917 2014-06-30 0001488917 us-gaap:PatentsMember 2015-07-01 2016-03-31 0001488917 us-gaap:TrademarksMember 2015-07-01 2016-03-31 0001488917 elmd:VentureBankMember us-gaap:RevolvingCreditFacilityMember 2015-07-01 2016-03-31 0001488917 elmd:InternationalMember 2014-07-01 2015-03-31 0001488917 elmd:InternationalMember 2015-07-01 2016-03-31 0001488917 us-gaap:RestrictedStockMember us-gaap:MaximumMember 2015-07-01 2016-03-31 0001488917 us-gaap:RestrictedStockMember us-gaap:MinimumMember 2015-07-01 2016-03-31 0001488917 us-gaap:RestrictedStockMember 2015-07-01 2016-03-31 0001488917 us-gaap:RestrictedStockMember 2016-03-31 0001488917 us-gaap:EmployeeStockOptionMember 2016-03-31 0001488917 us-gaap:EmployeeStockOptionMember 2015-07-01 2016-03-31 0001488917 2016-01-01 2016-03-31 0001488917 2015-01-01 2015-03-31 0001488917 us-gaap:LoansPayableMember 2016-03-31 0001488917 us-gaap:LoansPayableMember 2015-07-01 2016-03-31 0001488917 us-gaap:RestrictedStockMember us-gaap:DirectorMember 2015-07-01 2016-03-31 0001488917 us-gaap:DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsAbandonmentMember 2015-07-01 2016-03-31 0001488917 us-gaap:DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsAbandonmentMember 2014-07-01 2015-06-30 0001488917 2015-03-31 iso4217:USD xbrli:shares xbrli:pure iso4217:USD xbrli:shares false --06-30 Q3 2016 2016-03-31 10-Q 0001488917 Smaller Reporting Company Electromed, Inc. P3Y

538518

668796

6518816

7310731

13327320

13480253

45000

91815

123000

97931

163500

609900

159000

539900

17405054

20007484

12586997

15193949

3598240

4934112

1502702

2904811

0.01

13000000

8133857

8187112

8133857

8187112

81339

81871

700370

1255054

184000

P1Y1M6D

698000

789000

28000

116000

999842

927931

1039000

P15Y

P12Y

440000

723000

2072108

2325718

1527000

1630000

140000

155000

245000

128000

3481723

4055409

17405054

20007484

2279277

2888243

2016-12-18

2500000

48749

47632

1202446

1167166

182699

160488

208983

246761

397833

442603

660000

670000

700000

120000

179000

130000

139000

3635516

3388116

514672

2389951

17298995

14209239

599000

591000

6035700

4556977

P3Y

P1Y

P6M

53255

1.95

53255

1.95

220000

389000

163500

2.05

450800

599800

693000

13923331

15952075

122657

8187112

.255

938000

2015-12-18

2500000

0.5700

1210000

.05

8600

2018-12-18

10125000

-14500

1.80

2.80

2.62

190000

44100

30000

23255

1.80 2.15

1090000

8000

32000

-8000

-32000

Yes No No

21000

-294000

-358000

-27000

0.0350

337000

180785

1875279

837469

466625

37229

644000

256000

2519279

837469

722625

37229

-51150

-65484

-13064

-20355

2570429

902953

735689

57584

10814582

8951947

3891295

3099141

183043

237201

84410

78292

10631539

8714746

3806885

3020849

13385011

9854900

4626984

3156725

3913984

4354339

1408716

1400252

8215472

8131496

8287237

8166659

8133857

8114252

8133857

8114252

0.23

.10

0.06

0.00

0.23

0.10

0.06

.00

8525

2044

4978

371

1670347

1831189

583579

319717

22711

141854

220417

166368

791915

-98813

-46515

-233116

-337000

153465

78596

13672

14546

458850

459223

180785

-284558

-379609

27752

256806

379609

1335872

1402109

-49917

-49471

13520

14797

36397

34674

-288000

P5Y7M17D

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify"><td style="width: 0in"></td><td style="width: 0.75in; text-align: left">Note 1. </td><td style="text-align: justify">Interim Financial Reporting</td> </tr></table>   Basis of presentation: Electromed, Inc. (the Company) develops, manufactures and markets innovative airway clearance products that apply High Frequency Chest Wall Oscillation (HFCWO) therapy in pulmonary care for patients of all ages. The Company markets its products in the U.S. to the home health care and institutional markets for use by patients in personal residences, hospitals and clinics. The Company also sells internationally both directly and through distributors. International sales were approximately $591,000 and $599,000 for the nine months ended March 31, 2016 and 2015, respectively. Since its inception, the Company has operated in a single industry segment: developing, manufacturing and marketing medical equipment.   The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles for interim financial statements and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. In the opinion of management, the accompanying unaudited condensed financial statements reflect all adjustments consisting of normal recurring adjustments necessary for a fair presentation of the Companys financial position and results of operations as required by Regulation S-X. Interim results of operations are not necessarily indicative of the results that may be achieved for the full year. The financial statements and related notes do not include all information and footnotes required by U.S. generally accepted accounting principles for annual reports. This interim report should be read in conjunction with the financial statements included in the Companys Annual Report on Form 10-K for the fiscal year ended June 30, 2015 (fiscal 2015).   A summary of the Companys significant accounting policies follows:   Use of estimates: Management uses estimates and assumptions in preparing the condensed financial statements in accordance with accounting principles generally accepted in the U.S. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could vary from the estimates that were used. The Company believes the critical accounting policies that require the most significant assumptions and judgments in the preparation of its condensed financial statements include revenue recognition and the related estimation of selling price adjustments, allowance for doubtful accounts, inventory obsolescence, share-based compensation, income taxes and the warranty reserve.   Net income per common share: Net income is presented on a per share basis for both basic and diluted common shares. Basic net income per common share is computed using the weighted average number of common shares outstanding during the period, excluding any restricted stock awards which have not vested. The diluted net income per common share calculation includes outstanding restricted stock grants and assumes that all stock options were exercised and converted into common stock at the beginning of the period, unless their effect would be anti-dilutive. Common stock equivalents excluded from the calculation of diluted earnings per share because their impact was anti-dilutive was 159,000 and 163,500 for the three and nine months ended March 31, 2016, respectively, and 539,900 and 609,900 for the three and nine months ended March 31, 2015, respectively.   New accounting pronouncements: In May 2014, the Financial Accounting Standards Board (FASB) issued guidance creating Accounting Standards Codification (ASC) Section 606, Revenue from Contracts with Customers. The new section will replace ASC Section 605, Revenue Recognition and creates modifications to various other revenue accounting standards for specialized transactions and industries. The section is intended to conform revenue accounting principles with a concurrently issued International Financial Reporting Standards with previously differing treatment between U.S. practice and that of much of the rest of the world, as well as to enhance disclosures related to disaggregated revenue information. Entities will have the option to apply the standard retrospectively to all prior periods presented, or to apply it retrospectively only to contracts existing at the effective date, with the cumulative effect of the standard recorded as an adjustment to beginning retained earnings. The updated guidance will be effective for the Companys annual reporting period beginning with our fiscal year ending June 30, 2019, and interim periods within that year. The Company is evaluating the impact of this standard on its financial statements.   In April 2015, FASB issued Accounting Standards Update (ASU) 2015-03, Simplifying the Presentation of Debt Issuance Costs. This standard, which will become effective July 1, 2016 for the Company, requires that debt issuance costs be presented as a direct deduction from the carrying amount of long-term debt on the balance sheet. The new guidance aligns the presentation of debt issuance costs with debt discounts and premiums. The standard is to be applied retrospectively to all prior periods presented. As of March 31, 2016, the Company had approximately $21,000 of unamortized debt issuance costs recorded in other non-current assets on its balance sheet.    In July 2015, FASB issued ASU 2015-11, Inventory (Topic 330) Related to Simplifying the Measurement of Inventory, which applies to all inventory except that which is measured using last-in, first-out (LIFO) or the retail inventory method. Inventory measured using first-in, first-out (FIFO) or average cost is within the scope of the new guidance and should be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable cost of completion, disposal, and transportation. Subsequent measurement is unchanged for inventory measured using LIFO or the retail inventory method. The amendments will be effective for public business entities for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The new guidance should be applied prospectively, and earlier application is permitted as of the beginning of an interim or annual reporting period. The Company is evaluating the impact of the standard on its financial statements.   In November 2015, FASB issued ASU 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes. This standard requires that deferred tax assets and liabilities (DTAs and DTLs) be classified as noncurrent on the balance sheet rather than being separated into current and noncurrent. The ASU simplifies the current guidance (ASC 740-10-45-4), which requires entities to separately present DTAs and DTLs as current and noncurrent in a classified balance sheet.  ASU 2015-17 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. Early adoption is permitted and the standard may be applied either retrospectively or on a prospective basis to all deferred tax assets and liabilities. The Company has elected to adopt ASU 2015-17 early and it has been applied to its second quarter of fiscal 2016 on a prospective basis.   In February 2016, FASB issued ASU 2016-02, Leases. This standard requires the recognition of all lease transactions with terms in excess of 12 months on the balance sheet as a lease liability and a right-of-use asset (as defined in the standard). ASU 2016-02 will be effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with earlier application permitted.  Upon adoption, the lessee will apply the new standard retrospectively to all periods presented or retrospectively using a cumulative effect adjustment in the year of adoption. The Company is currently assessing the effect that ASU 2016-02 will have on its financial statements.   In March 2016, FASB issued ASU 2016-09, CompensationStock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, which reduces complexity in accounting standards related to share-based payment transactions, including, among others, (1) accounting for income taxes, (2) classification of excess tax benefits on the statement of cash flow, (3) forfeitures, and (4) statutory tax withholding requirements.  The ASU will be effective for annual reporting periods beginning on or after December 15, 2016, and interim periods within those annual periods, with earlier application permitted.  The Company is evaluating the impact of the standard on its financial statements.   Reclassifications: Certain items in the financial statements for fiscal 2015 have been reclassified to be consistent with the classifications adopted for the Companys fiscal year ending June 30, 2016. The fiscal 2015 reclassifications had no impact on previously reported net income or equity.

The components of inventory were approximately as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31, 2016</td><td style="padding-bottom: 1pt; font-weight: bold; border-bottom: Black 1pt solid"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2015</td><td style="padding-bottom: 1pt; font-weight: bold; border-bottom: Black 1pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="width: 70%; text-align: left">Parts inventory	</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,630,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,527,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Work in process	</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">128,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">245,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="text-align: left">Finished goods	</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">723,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">440,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: Reserve for obsolescence	</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(155,000</td><td style="border-bottom: Black 1pt solid; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(140,000</td><td style="border-bottom: Black 1pt solid; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="padding-bottom: 3pt">Total	</td><td style="padding-bottom: 3pt"> </td> <td style="border-bottom: Black 3pt double; text-align: left">$</td><td style="border-bottom: Black 3pt double; text-align: right">2,326,000</td><td style="border-bottom: Black 3pt double; text-align: left"> </td><td style="padding-bottom: 3pt"> </td> <td style="border-bottom: Black 3pt double; text-align: left">$</td><td style="border-bottom: Black 3pt double; text-align: right">2,072,000</td><td style="border-bottom: Black 3pt double; text-align: left"> </td></tr> </table>

The activity and balances of finite-life intangible assets were approximately as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: center"> </td><td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine Months Ended March 31, 2016</td><td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold; border-bottom: Black 1pt solid"> </td><td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fiscal Year Ended  June 30, 2015</td><td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold; border-bottom: Black 1pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="width: 70%; text-align: left">Balance, beginning 	</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,039,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 9pt">Additions 	</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">28,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">116,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="padding-left: 9pt">Abandonments	</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(8,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(32,000</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Amortization expense 	</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(92,000</td><td style="border-bottom: Black 1pt solid; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(123,000</td><td style="border-bottom: Black 1pt solid; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="padding-bottom: 3pt">Balance, ending 	</td><td style="padding-bottom: 3pt"> </td> <td style="border-bottom: Black 3pt double; text-align: left">$</td><td style="border-bottom: Black 3pt double; text-align: right">928,000</td><td style="border-bottom: Black 3pt double; text-align: left"> </td><td style="padding-bottom: 3pt"> </td> <td style="border-bottom: Black 3pt double; text-align: left">$</td><td style="border-bottom: Black 3pt double; text-align: right">1,000,000</td><td style="border-bottom: Black 3pt double; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify"><td style="width: 0.75in; text-align: left">Note 4.	</td><td style="text-align: justify">Warranty Liability</td> </tr></table>   The Company provides a lifetime warranty on its products to the prescribed patient for sales within the U.S. and a three-year warranty for all institutional sales and sales to individuals outside the U.S. The Company estimates the costs that may be incurred under its warranty and records a liability in the amount of such costs at the time the product is shipped. Factors that affect the Companys warranty liability include the number of units shipped, historical and anticipated rates of warranty claims, the products useful life and cost per claim. The Company periodically assesses the adequacy of its recorded warranty liability and adjusts the amounts as necessary.   Changes in the Companys warranty liability were approximately as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine Months Ended March 31, 2016</td><td style="padding-bottom: 1pt; font-weight: bold; border-bottom: Black 1pt solid"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fiscal Year Ended June 30, 2015</td><td style="padding-bottom: 1pt; font-weight: bold; border-bottom: Black 1pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="width: 70%; text-align: left">Beginning warranty reserve	</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">660,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">700,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 9pt">Accrual for products sold	</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">130,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">139,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Expenditures and costs incurred for warranty claims	</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(120,000</td><td style="border-bottom: Black 1pt solid; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(179,000</td><td style="border-bottom: Black 1pt solid; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 3pt">Ending warranty reserve	</td><td style="padding-bottom: 3pt"> </td> <td style="border-bottom: Black 3pt double; text-align: left">$</td><td style="border-bottom: Black 3pt double; text-align: right">670,000</td><td style="border-bottom: Black 3pt double; text-align: left"> </td><td style="padding-bottom: 3pt"> </td> <td style="border-bottom: Black 3pt double; text-align: left">$</td><td style="border-bottom: Black 3pt double; text-align: right">660,000</td><td style="border-bottom: Black 3pt double; text-align: left"> </td></tr> </table>

Changes in the Companys warranty liability were approximately as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine Months Ended March 31, 2016</td><td style="padding-bottom: 1pt; font-weight: bold; border-bottom: Black 1pt solid"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fiscal Year Ended June 30, 2015</td><td style="padding-bottom: 1pt; font-weight: bold; border-bottom: Black 1pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="width: 70%; text-align: left">Beginning warranty reserve	</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">660,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">700,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 9pt">Accrual for products sold	</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">130,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">139,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Expenditures and costs incurred for warranty claims	</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(120,000</td><td style="border-bottom: Black 1pt solid; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(179,000</td><td style="border-bottom: Black 1pt solid; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 3pt">Ending warranty reserve	</td><td style="padding-bottom: 3pt"> </td> <td style="border-bottom: Black 3pt double; text-align: left">$</td><td style="border-bottom: Black 3pt double; text-align: right">670,000</td><td style="border-bottom: Black 3pt double; text-align: left"> </td><td style="padding-bottom: 3pt"> </td> <td style="border-bottom: Black 3pt double; text-align: left">$</td><td style="border-bottom: Black 3pt double; text-align: right">660,000</td><td style="border-bottom: Black 3pt double; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify"><td style="width: 0.75in; text-align: left">Note 7.	 </td><td style="text-align: justify">Stock-Based Compensation</td> </tr></table>   The Company recorded $153,000, and $79,000 of compensation expense related to current and past grants of stock options and restricted stock for the nine months ended March 31, 2016 and 2015, respectively. This expense is included in selling, general and administrative expense. As of March 31, 2016, approximately $184,000 of total unrecognized compensation expense related to non-vested equity awards is expected to be recognized over a weighted average period of approximately 1.1 years.   Stock Options   The Company issued 163,500 stock options pursuant to its 2014 Stock Compensation Plan during the nine months ended March 31, 2016. Stock option transactions during the nine months ended March 31, 2016 are summarized as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold; border-bottom: Black 1pt solid"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold; border-bottom: Black 1pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="width: 70%">Outstanding at June 30, 2015	</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">450,800</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: center"></td><td style="width: 10%; text-align: center">$2.80</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 9pt">Granted	</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">163,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"></td><td style="text-align: center">$2.05</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="padding-left: 9pt">Exercised	</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Cancelled or Forfeited	</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(14,500</td><td style="border-bottom: Black 1pt solid; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center"></td><td style="text-align: center; padding-bottom: 1">$1.80</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="padding-bottom: 3pt">Outstanding at March 31, 2016	</td><td style="padding-bottom: 3pt"> </td> <td style="border-bottom: Black 3pt double; text-align: left"> </td><td style="border-bottom: Black 3pt double; text-align: right">599,800</td><td style="border-bottom: Black 3pt double; text-align: left"> </td><td style="padding-bottom: 3pt"> </td> <td style="text-align: center"></td><td style="text-align: center; padding-bottom: 3">$2.62</td><td style="text-align: left"> </td></tr> </table>   The intrinsic value of an option is the amount by which the fair value of the underlying stock exceeds its exercise price. At March 31, 2016, the weighted average remaining contractual term for all outstanding stock options was 5.63 years and their aggregate intrinsic value was approximately $693,000. During the nine months ended March 31, 2016, 190,000 options issued in conjunction with the Companys 2010 initial public offering and 44,100 warrants issued with convertible debt, prior to 2010, expired. Outstanding at March 31, 2016 were the 599,800 employee stock options, of which approximately 389,000 are exercisable and have an aggregate intrinsic value of approximately $220,000.    Restricted Stock   The Companys 2014 Stock Compensation Plan permits its Compensation Committee to grant other stock-based awards. The Company makes restricted stock grants to key employees and non-employee directors that vest over six months to three years.   During the nine months ended March 31, 2016, the Company issued restricted stock awards to employees totaling 30,000 shares of common stock, with a vesting term of one to three years and a fair value of $1.80 per share, and to directors totaling 23,255 shares of common stock, with a vesting term of six months and a fair value of $2.15 per share. Restricted stock transactions during the nine months ended March 31, 2016 are summarized as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td colspan="2" style="font-weight: bold; padding-bottom: 1pt; text-align: center; border-bottom: Black 1pt solid">Number of Shares</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td colspan="2" style="font-weight: bold; padding-bottom: 1pt; text-align: center; border-bottom: Black 1pt solid">Weighted Average Grant Date Fair Value</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="text-align: left; width: 68%">Unvested shares at June 30, 2015	</td><td style="text-align: left; width: 3%"> </td><td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 10%"></td><td style="text-align: left; width: 1%"> </td><td style="width: 3%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: center; width: 10%"></td><td style="text-align: left; width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0.125in">Granted	</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">53,255</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: center">$1.95</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="text-align: left; padding-left: 0.125in">Vested	</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0.125in">Forfeited	</td><td style="text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"></td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: center"></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="text-align: left">Unvested at March 31, 2016	</td><td style="text-align: left"> </td><td style="padding-bottom: 3pt"> </td> <td style="border-bottom: Black 3pt double; text-align: left"> </td><td style="border-bottom: Black 3pt double; text-align: right">53,255</td><td style="border-bottom: Black 3pt double; text-align: left"> </td><td style="padding-bottom: 3pt"> </td> <td style="text-align: left"> </td><td style="text-align: center; padding-bottom: 3">$1.95</td><td style="text-align: left"> </td></tr> </table>

Stock option transactions during the nine months ended March 31, 2016 are summarized as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold; border-bottom: Black 1pt solid"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold; border-bottom: Black 1pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="width: 70%">Outstanding at June 30, 2015	</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">450,800</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: center"></td><td style="width: 10%; text-align: center">$2.80</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 9pt">Granted	</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">163,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"></td><td style="text-align: center">$2.05</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="padding-left: 9pt">Exercised	</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Cancelled or Forfeited	</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(14,500</td><td style="border-bottom: Black 1pt solid; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center"></td><td style="text-align: center; padding-bottom: 1">$1.80</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="padding-bottom: 3pt">Outstanding at March 31, 2016	</td><td style="padding-bottom: 3pt"> </td> <td style="border-bottom: Black 3pt double; text-align: left"> </td><td style="border-bottom: Black 3pt double; text-align: right">599,800</td><td style="border-bottom: Black 3pt double; text-align: left"> </td><td style="padding-bottom: 3pt"> </td> <td style="text-align: center"></td><td style="text-align: center; padding-bottom: 3">$2.62</td><td style="text-align: left"> </td></tr> </table>

Use of estimates: Management uses estimates and assumptions in preparing the condensed financial statements in accordance with accounting principles generally accepted in the U.S. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could vary from the estimates that were used. The Company believes the critical accounting policies that require the most significant assumptions and judgments in the preparation of its condensed financial statements include revenue recognition and the related estimation of selling price adjustments, allowance for doubtful accounts, inventory obsolescence, share-based compensation, income taxes and the warranty reserve.

Net income per common share: Net income is presented on a per share basis for both basic and diluted common shares. Basic net income per common share is computed using the weighted average number of common shares outstanding during the period, excluding any restricted stock awards which have not vested. The diluted net income per common share calculation includes outstanding restricted stock grants and assumes that all stock options were exercised and converted into common stock at the beginning of the period, unless their effect would be anti-dilutive. Common stock equivalents excluded from the calculation of diluted earnings per share because their impact was anti-dilutive was 159,000 and 163,500 for the three and nine months ended March 31, 2016, respectively, and 539,900 and 609,900 for the three and nine months ended March 31, 2015, respectively.

New accounting pronouncements: In May 2014, the Financial Accounting Standards Board (FASB) issued guidance creating Accounting Standards Codification (ASC) Section 606, Revenue from Contracts with Customers. The new section will replace ASC Section 605, Revenue Recognition and creates modifications to various other revenue accounting standards for specialized transactions and industries. The section is intended to conform revenue accounting principles with a concurrently issued International Financial Reporting Standards with previously differing treatment between U.S. practice and that of much of the rest of the world, as well as to enhance disclosures related to disaggregated revenue information. Entities will have the option to apply the standard retrospectively to all prior periods presented, or to apply it retrospectively only to contracts existing at the effective date, with the cumulative effect of the standard recorded as an adjustment to beginning retained earnings. The updated guidance will be effective for the Companys annual reporting period beginning with our fiscal year ending June 30, 2019, and interim periods within that year. The Company is evaluating the impact of this standard on its financial statements.   In April 2015, FASB issued Accounting Standards Update (ASU) 2015-03, Simplifying the Presentation of Debt Issuance Costs. This standard, which will become effective July 1, 2016 for the Company, requires that debt issuance costs be presented as a direct deduction from the carrying amount of long-term debt on the balance sheet. The new guidance aligns the presentation of debt issuance costs with debt discounts and premiums. The standard is to be applied retrospectively to all prior periods presented. As of March 31, 2016, the Company had approximately $21,000 of unamortized debt issuance costs recorded in other non-current assets on its balance sheet.    In July 2015, FASB issued ASU 2015-11, Inventory (Topic 330) Related to Simplifying the Measurement of Inventory, which applies to all inventory except that which is measured using last-in, first-out (LIFO) or the retail inventory method. Inventory measured using first-in, first-out (FIFO) or average cost is within the scope of the new guidance and should be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable cost of completion, disposal, and transportation. Subsequent measurement is unchanged for inventory measured using LIFO or the retail inventory method. The amendments will be effective for public business entities for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The new guidance should be applied prospectively, and earlier application is permitted as of the beginning of an interim or annual reporting period. The Company is evaluating the impact of the standard on its financial statements.   In November 2015, FASB issued ASU 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes. This standard requires that deferred tax assets and liabilities (DTAs and DTLs) be classified as noncurrent on the balance sheet rather than being separated into current and noncurrent. The ASU simplifies the current guidance (ASC 740-10-45-4), which requires entities to separately present DTAs and DTLs as current and noncurrent in a classified balance sheet.  ASU 2015-17 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. Early adoption is permitted and the standard may be applied either retrospectively or on a prospective basis to all deferred tax assets and liabilities. The Company has elected to adopt ASU 2015-17 early and it has been applied to its second quarter of fiscal 2016 on a prospective basis.   In February 2016, FASB issued ASU 2016-02, Leases. This standard requires the recognition of all lease transactions with terms in excess of 12 months on the balance sheet as a lease liability and a right-of-use asset (as defined in the standard). ASU 2016-02 will be effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with earlier application permitted.  Upon adoption, the lessee will apply the new standard retrospectively to all periods presented or retrospectively using a cumulative effect adjustment in the year of adoption. The Company is currently assessing the effect that ASU 2016-02 will have on its financial statements.   In March 2016, FASB issued ASU 2016-09, CompensationStock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, which reduces complexity in accounting standards related to share-based payment transactions, including, among others, (1) accounting for income taxes, (2) classification of excess tax benefits on the statement of cash flow, (3) forfeitures, and (4) statutory tax withholding requirements.  The ASU will be effective for annual reporting periods beginning on or after December 15, 2016, and interim periods within those annual periods, with earlier application permitted.  The Company is evaluating the impact of the standard on its financial statements.

Reclassifications: Certain items in the financial statements for fiscal 2015 have been reclassified to be consistent with the classifications adopted for the Companys fiscal year ending June 30, 2016. The fiscal 2015 reclassifications had no impact on previously reported net income or equity.

Restricted stock transactions during the nine months ended March 31, 2016 are summarized as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td colspan="2" style="font-weight: bold; padding-bottom: 1pt; text-align: center; border-bottom: Black 1pt solid">Number of Shares</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td colspan="2" style="font-weight: bold; padding-bottom: 1pt; text-align: center; border-bottom: Black 1pt solid">Weighted Average Grant Date Fair Value</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="text-align: left; width: 68%">Unvested shares at June 30, 2015	</td><td style="text-align: left; width: 3%"> </td><td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 10%"></td><td style="text-align: left; width: 1%"> </td><td style="width: 3%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: center; width: 10%"></td><td style="text-align: left; width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0.125in">Granted	</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">53,255</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: center">$1.95</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="text-align: left; padding-left: 0.125in">Vested	</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0.125in">Forfeited	</td><td style="text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"></td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: center"></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="text-align: left">Unvested at March 31, 2016	</td><td style="text-align: left"> </td><td style="padding-bottom: 3pt"> </td> <td style="border-bottom: Black 3pt double; text-align: left"> </td><td style="border-bottom: Black 3pt double; text-align: right">53,255</td><td style="border-bottom: Black 3pt double; text-align: left"> </td><td style="padding-bottom: 3pt"> </td> <td style="text-align: left"> </td><td style="text-align: center; padding-bottom: 3">$1.95</td><td style="text-align: left"> </td></tr> </table>

EX-101.SCH 7 elmd-20160331.xsd XBRL SCHEMA FILE 00000001 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Statements Of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Statements Of Operations (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Statements Of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Interim Financial Reporting link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Finite-Life Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Warranty Liability link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Financing Arrangements link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Commitments And Contingencies link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Interim Financial Reporting (Policies) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Finite-Life Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Warranty Liability (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Interim Financial Reporting (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Finite-Life Intangible Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Finite-Life Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Warranty Liability (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Warranty Liability (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Income Taxes (Details Narrative) ) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Financing Arrangements (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Stock-Based Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Stock-Based Compensation (Details 1) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 elmd-20160331_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 elmd-20160331_def.xml XBRL DEFINITION FILE EX-101.LAB 10 elmd-20160331_lab.xml XBRL LABEL FILE Venture Bank [Member] Lender Name [Axis] Revolving Credit Facility [Member] Debt Instrument [Axis] Employee Stock Options [Member] Award Type [Axis] Institutional Sales and Sales Outside United States [Member] Concentration Risk Benchmark [Axis] Patents [Member] Finite-Lived Intangible Assets by Major Class [Axis] Trademarks [Member] International [Member] Geographical [Axis] Restricted Stock Awards [Member] Maximum [Member] Range [Axis] Minimum [Member] Term Loan [Member] Debt Instrument [Axis] Directors [Member] Title of Individual [Axis] Abandonment [Member] Disposal Group Classification [Axis] Document And Entity Information [Abstract] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] Assets Current Assets Cash Accounts receivable (net of allowances for doubtful accounts of $45,000) Inventories Prepaid expenses and other current assets Income tax receivable Total current assets Property and equipment, net Finite-life intangible assets, net Other assets Deferred income taxes Total assets Liabilities and Shareholders' Equity Current Liabilities Current maturities of long-term debt Accounts payable Accrued compensation Income tax payable Warranty reserve Other accrued liabilities Total current liabilities Long-term debt, less current maturities Total liabilities Commitments and Contingencies Equity Common stock, $0.01 par value; authorized: 13,000,000 shares; 8,187,112 and 8,133,857 issued and outstanding at March 31, 2016 and June 30, 2015, respectively Additional paid-in capital Retained earnings Total shareholders' equity Total liabilities and shareholders' equity Accounts receivable, allowance for doubtful accounts Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Net revenues Cost of revenues Gross profit Operating expenses Selling, general and administrative Research and development Total operating expenses Operating income Interest expense, net of interest income of $4,978, $371, $8,525 and $2,044, respectively Net income before income taxes Income tax expense Net income Income per share: Basic Diluted Weighted-average common shares outstanding: Basic Diluted Interest income Statement of Cash Flows [Abstract] Cash Flows From Operating Activities Net income Adjustments to reconcile net income to net cash provided by operating activities: Depreciation Amortization of finite-life intangible assets Amortization of debt issuance costs Share-based compensation expense Deferred taxes Loss on disposal of property and equipment and intangibles assets Changes in operating assets and liabilities: Accounts receivable Inventories Prepaid expenses and other assets Income tax receivable Accounts payable and accrued liabilities Net cash provided by operating activities Cash Flows From Investing Activities Expenditures for property and equipment Expenditures for finite-life intangible assets Net cash used in investing activities Cash Flows From Financing Activities Principal payments on long-term debt including capital lease obligations Payment of deferred financing fees Net cash used in financing activities Net increase in cash Cash Beginning of period End of period Organization, Consolidation and Presentation of Financial Statements [Abstract] Interim Financial Reporting Inventory Disclosure [Abstract] Inventories Goodwill and Intangible Assets Disclosure [Abstract] Finite-Life Intangible Assets Product Warranties Disclosures [Abstract] Warranty Liability Income Tax Disclosure [Abstract] Income Taxes Debt Disclosure [Abstract] Financing Arrangements Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Stock-Based Compensation Commitments and Contingencies Disclosure [Abstract] Commitments And Contingencies Use of Estimates Net Income Per Common Share New Accounting Pronouncements Reclassifications Schedule Of Components Of Inventory Schedule Of Finite-Life Intangible Assets Schedule Of Warranty Liability Schedule Of Stock Compensation Plan Activity Schedule Of Restricted Stock Awards Activity Statement [Table] Statement [Line Items] Sales Common stock equivalents excluded from calculation of diluted earnings per share Unamortized debt issuance costs recorded in other non-current assets Parts inventory Work in process Finished goods Less: Reserve for obsolescence Total Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets [Line Items] Estimated useful life Abandonment expense of patents Accumulated amortization Balance, beginning Additions Abandonments Amortization expense Balance, ending Warranty term Beginning warranty reserve Accrual for products sold Expenditures and costs incurred for warranty claims Ending warranty reserve Effective tax rate Income tax expense (benefit) Current tax expense (benefit) Change in valuation allowance on deferred tax assets Income tax benefit - deferred taxes Line of Credit Facility [Table] Line of Credit Facility [Line Items] Long-term Debt, Type [Axis] Maximum borrowing capacity Credit facility effective date Credit facility expiration date Effective interest rate including prime rate Borrowing capacity of eligible accounts receivable Borrowing capacity of eligible accounts receivable (percent) Principal loan amount Term loan, interest rate Monthly payments of principal and interest Final payment of principal and interest Term loan maturity date Minimum tangible net worth to be maintained Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Award vesting period Weighted average remaining contractual term EX-101.PRE 11 elmd-20160331_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Mar. 31, 2016	May. 06, 2016
Document And Entity Information [Abstract]
Entity Registrant Name	Electromed, Inc.
Entity Central Index Key	0001488917
Document Type	10-Q
Document Period End Date	Mar. 31, 2016
Amendment Flag	false
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Current Fiscal Year End Date	--06-30
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		8,187,112
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2016

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2016	Jun. 30, 2015
Current Assets
Cash	$ 4,934,112	$ 3,598,240
Accounts receivable (net of allowances for doubtful accounts of $45,000)	7,310,731	6,518,816
Inventories	2,325,718	2,072,108
Prepaid expenses and other current assets	442,603	397,833
Income tax receivable	180,785
Total current assets	15,193,949	12,586,997
Property and equipment, net	3,388,116	3,635,516
Finite-life intangible assets, net	927,931	999,842
Other assets	160,488	182,699
Deferred income taxes	337,000
Total assets	20,007,484	17,405,054
Current Liabilities
Current maturities of long-term debt	47,632	48,749
Accounts payable	668,796	538,518
Accrued compensation	$ 1,255,054	700,370
Income tax payable		122,657
Warranty reserve	$ 670,000	660,000
Other accrued liabilities	246,761	208,983
Total current liabilities	2,888,243	2,279,277
Long-term debt, less current maturities	1,167,166	1,202,446
Total liabilities	$ 4,055,409	$ 3,481,723
Commitments and Contingencies
Equity
Common stock, $0.01 par value; authorized: 13,000,000 shares; 8,187,112 and 8,133,857 issued and outstanding at March 31, 2016 and June 30, 2015, respectively	$ 81,871	$ 81,339
Additional paid-in capital	13,480,253	13,327,320
Retained earnings	2,389,951	514,672
Total shareholders' equity	15,952,075	13,923,331
Total liabilities and shareholders' equity	$ 20,007,484	$ 17,405,054

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Mar. 31, 2016	Jun. 30, 2015
Statement of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 45,000	$ 45,000
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	13,000,000	13,000,000
Common stock, shares issued	8,187,112	8,133,857
Common stock, shares outstanding	8,187,112	8,133,857

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Statements Of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Income Statement [Abstract]
Net revenues	$ 6,035,700	$ 4,556,977	$ 17,298,995	$ 14,209,239
Cost of revenues	1,408,716	1,400,252	3,913,984	4,354,339
Gross profit	4,626,984	3,156,725	13,385,011	9,854,900
Operating expenses
Selling, general and administrative	3,806,885	3,020,849	10,631,539	8,714,746
Research and development	84,410	78,292	183,043	237,201
Total operating expenses	3,891,295	3,099,141	10,814,582	8,951,947
Operating income	735,689	57,584	2,570,429	902,953
Interest expense, net of interest income of $4,978, $371, $8,525 and $2,044, respectively	13,064	20,355	51,150	65,484
Net income before income taxes	722,625	37,229	2,519,279	837,469
Income tax expense	(256,000)		(644,000)
Net income	$ 466,625	$ 37,229	$ 1,875,279	$ 837,469
Income per share:
Basic	$ 0.06	$ .00	$ 0.23	$ 0.10
Diluted	$ 0.06	$ 0.00	$ 0.23	$ .10
Weighted-average common shares outstanding:
Basic	8,133,857	8,114,252	8,133,857	8,114,252
Diluted	8,287,237	8,166,659	8,215,472	8,131,496

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Statements Of Operations (Unaudited) (Parenthetical) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Income Statement [Abstract]
Interest income	$ 4,978	$ 371	$ 8,525	$ 2,044

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Statements Of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash Flows From Operating Activities
Net income	$ 1,875,279	$ 837,469
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	458,850	459,223
Amortization of finite-life intangible assets	91,815	97,931
Amortization of debt issuance costs	13,672	14,546
Share-based compensation expense	153,465	$ 78,596
Deferred taxes	(337,000)
Loss on disposal of property and equipment and intangibles assets	46,515	$ 233,116
Changes in operating assets and liabilities:
Accounts receivable	(791,915)	98,813
Inventories	(220,417)	(166,368)
Prepaid expenses and other assets	(22,711)	$ (141,854)
Income tax receivable	(180,785)
Accounts payable and accrued liabilities	583,579	$ 319,717
Net cash provided by operating activities	1,670,347	1,831,189
Cash Flows From Investing Activities
Expenditures for property and equipment	(256,806)	$ (379,609)
Expenditures for finite-life intangible assets	(27,752)
Net cash used in investing activities	(284,558)	$ (379,609)
Cash Flows From Financing Activities
Principal payments on long-term debt including capital lease obligations	(36,397)	(34,674)
Payment of deferred financing fees	(13,520)	(14,797)
Net cash used in financing activities	(49,917)	(49,471)
Net increase in cash	1,335,872	1,402,109
Cash
Beginning of period	3,598,240	1,502,702
End of period	$ 4,934,112	$ 2,904,811

XML 18 R7.htm IDEA: XBRL DOCUMENT

Interim Financial Reporting

9 Months Ended

Mar. 31, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Interim Financial Reporting

Note 1.

Interim Financial Reporting

A summary of the Company’s significant accounting policies follows:

XML 19 R8.htm IDEA: XBRL DOCUMENT

Inventories

9 Months Ended

Mar. 31, 2016

Inventory Disclosure [Abstract]

Inventories

Note 2.

Inventories

The components of inventory were approximately as follows:

	March 31, 2016			June 30, 2015
Parts inventory	$	1,630,000		$	1,527,000
Work in process		128,000			245,000
Finished goods		723,000			440,000
Less: Reserve for obsolescence		(155,000	)		(140,000	)
Total	$	2,326,000		$	2,072,000

XML 20 R9.htm IDEA: XBRL DOCUMENT

Finite-Life Intangible Assets

9 Months Ended

Mar. 31, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Finite-Life Intangible Assets

Note 3.

Finite-life Intangible Assets

The activity and balances of finite-life intangible assets were approximately as follows:

	Nine Months Ended March 31, 2016			Fiscal Year Ended June 30, 2015
Balance, beginning	$	1,000,000		$	1,039,000
Additions		28,000			116,000
Abandonments		(8,000	)		(32,000	)
Amortization expense		(92,000	)		(123,000	)
Balance, ending	$	928,000		$	1,000,000

XML 21 R10.htm IDEA: XBRL DOCUMENT

Warranty Liability

9 Months Ended

Mar. 31, 2016

Product Warranties Disclosures [Abstract]

Warranty Liability

Note 4.

Warranty Liability

Changes in the Company’s warranty liability were approximately as follows:

	Nine Months Ended March 31, 2016			Fiscal Year Ended June 30, 2015
Beginning warranty reserve	$	660,000		$	700,000
Accrual for products sold		130,000			139,000
Expenditures and costs incurred for warranty claims		(120,000	)		(179,000	)
Ending warranty reserve	$	670,000		$	660,000

XML 22 R11.htm IDEA: XBRL DOCUMENT

Income Taxes

9 Months Ended

Mar. 31, 2016

Income Tax Disclosure [Abstract]

Income Taxes

Note 5.

Income Taxes

Taxable income in prior carryback years, if carryback is permitted under the tax law;

Future reversals of existing taxable temporary differences, excluding those related to indefinite-lived intangible assets;

Tax planning strategies; and

Future taxable income exclusive of reversing temporary differences and carryforwards.

XML 23 R12.htm IDEA: XBRL DOCUMENT

Financing Arrangements

9 Months Ended

Mar. 31, 2016

Debt Disclosure [Abstract]

Financing Arrangements

Note 6.

Financing Arrangements

XML 24 R13.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation

9 Months Ended

Mar. 31, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock-Based Compensation

Note 7.

Stock-Based Compensation

Stock Options

	Number of Shares			Weighted Average Exercise Price
Outstanding at June 30, 2015		450,800			$2.80
Granted		163,500			$2.05
Exercised		–			–
Cancelled or Forfeited		(14,500	)		$1.80
Outstanding at March 31, 2016		599,800			$2.62

Restricted Stock

	Number of Shares		Weighted Average Grant Date Fair Value
Unvested shares at June 30, 2015		–		–
Granted		53,255		$1.95
Vested		–		–
Forfeited		–		–
Unvested at March 31, 2016		53,255		$1.95

XML 25 R14.htm IDEA: XBRL DOCUMENT

Commitments And Contingencies

9 Months Ended

Mar. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

Commitments And Contingencies

Note 8.

Commitments and Contingencies

XML 26 R15.htm IDEA: XBRL DOCUMENT

Interim Financial Reporting (Policies)	9 Months Ended
Interim Financial Reporting (Policies)	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Use of Estimates	Use of estimates: Management uses estimates and assumptions in preparing the condensed financial statements in accordance with accounting principles generally accepted in the U.S. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could vary from the estimates that were used. The Company believes the critical accounting policies that require the most significant assumptions and judgments in the preparation of its condensed financial statements include revenue recognition and the related estimation of selling price adjustments, allowance for doubtful accounts, inventory obsolescence, share-based compensation, income taxes and the warranty reserve.
Net Income Per Common Share	Net income per common share: Net income is presented on a per share basis for both basic and diluted common shares. Basic net income per common share is computed using the weighted average number of common shares outstanding during the period, excluding any restricted stock awards which have not vested. The diluted net income per common share calculation includes outstanding restricted stock grants and assumes that all stock options were exercised and converted into common stock at the beginning of the period, unless their effect would be anti-dilutive. Common stock equivalents excluded from the calculation of diluted earnings per share because their impact was anti-dilutive was 159,000 and 163,500 for the three and nine months ended March 31, 2016, respectively, and 539,900 and 609,900 for the three and nine months ended March 31, 2015, respectively.
New Accounting Pronouncements	New accounting pronouncements: In May 2014, the Financial Accounting Standards Board (“FASB”) issued guidance creating Accounting Standards Codification (“ASC”) Section 606, “Revenue from Contracts with Customers”. The new section will replace ASC Section 605, “Revenue Recognition” and creates modifications to various other revenue accounting standards for specialized transactions and industries. The section is intended to conform revenue accounting principles with a concurrently issued International Financial Reporting Standards with previously differing treatment between U.S. practice and that of much of the rest of the world, as well as to enhance disclosures related to disaggregated revenue information. Entities will have the option to apply the standard retrospectively to all prior periods presented, or to apply it retrospectively only to contracts existing at the effective date, with the cumulative effect of the standard recorded as an adjustment to beginning retained earnings. The updated guidance will be effective for the Company’s annual reporting period beginning with our fiscal year ending June 30, 2019, and interim periods within that year. The Company is evaluating the impact of this standard on its financial statements. In April 2015, FASB issued Accounting Standards Update (“ASU”) 2015-03, “Simplifying the Presentation of Debt Issuance Costs.” This standard, which will become effective July 1, 2016 for the Company, requires that debt issuance costs be presented as a direct deduction from the carrying amount of long-term debt on the balance sheet. The new guidance aligns the presentation of debt issuance costs with debt discounts and premiums. The standard is to be applied retrospectively to all prior periods presented. As of March 31, 2016, the Company had approximately $21,000 of unamortized debt issuance costs recorded in other non-current assets on its balance sheet. In July 2015, FASB issued ASU 2015-11, “Inventory (Topic 330) Related to Simplifying the Measurement of Inventory,” which applies to all inventory except that which is measured using last-in, first-out (“LIFO”) or the retail inventory method. Inventory measured using first-in, first-out (“FIFO”) or average cost is within the scope of the new guidance and should be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable cost of completion, disposal, and transportation. Subsequent measurement is unchanged for inventory measured using LIFO or the retail inventory method. The amendments will be effective for public business entities for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The new guidance should be applied prospectively, and earlier application is permitted as of the beginning of an interim or annual reporting period. The Company is evaluating the impact of the standard on its financial statements. In November 2015, FASB issued ASU 2015-17, “Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes.” This standard requires that deferred tax assets and liabilities (“DTAs” and “DTLs”) be classified as noncurrent on the balance sheet rather than being separated into current and noncurrent. The ASU simplifies the current guidance (ASC 740-10-45-4), which requires entities to separately present DTAs and DTLs as current and noncurrent in a classified balance sheet. ASU 2015-17 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. Early adoption is permitted and the standard may be applied either retrospectively or on a prospective basis to all deferred tax assets and liabilities. The Company has elected to adopt ASU 2015-17 early and it has been applied to its second quarter of fiscal 2016 on a prospective basis. In February 2016, FASB issued ASU 2016-02, “Leases.” This standard requires the recognition of all lease transactions with terms in excess of 12 months on the balance sheet as a lease liability and a right-of-use asset (as defined in the standard). ASU 2016-02 will be effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with earlier application permitted. Upon adoption, the lessee will apply the new standard retrospectively to all periods presented or retrospectively using a cumulative effect adjustment in the year of adoption. The Company is currently assessing the effect that ASU 2016-02 will have on its financial statements. In March 2016, FASB issued ASU 2016-09, “Compensation–Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting”, which reduces complexity in accounting standards related to share-based payment transactions, including, among others, (1) accounting for income taxes, (2) classification of excess tax benefits on the statement of cash flow, (3) forfeitures, and (4) statutory tax withholding requirements. The ASU will be effective for annual reporting periods beginning on or after December 15, 2016, and interim periods within those annual periods, with earlier application permitted. The Company is evaluating the impact of the standard on its financial statements.
Reclassifications	Reclassifications: Certain items in the financial statements for fiscal 2015 have been reclassified to be consistent with the classifications adopted for the Company’s fiscal year ending June 30, 2016. The fiscal 2015 reclassifications had no impact on previously reported net income or equity.

XML 27 R16.htm IDEA: XBRL DOCUMENT

Inventories (Tables)

9 Months Ended

Mar. 31, 2016

Inventory Disclosure [Abstract]

Schedule Of Components Of Inventory

The components of inventory were approximately as follows:

	March 31, 2016			June 30, 2015
Parts inventory	$	1,630,000		$	1,527,000
Work in process		128,000			245,000
Finished goods		723,000			440,000
Less: Reserve for obsolescence		(155,000	)		(140,000	)
Total	$	2,326,000		$	2,072,000

XML 28 R17.htm IDEA: XBRL DOCUMENT

Finite-Life Intangible Assets (Tables)

9 Months Ended

Mar. 31, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule Of Finite-Life Intangible Assets

The activity and balances of finite-life intangible assets were approximately as follows:

	Nine Months Ended March 31, 2016			Fiscal Year Ended June 30, 2015
Balance, beginning	$	1,000,000		$	1,039,000
Additions		28,000			116,000
Abandonments		(8,000	)		(32,000	)
Amortization expense		(92,000	)		(123,000	)
Balance, ending	$	928,000		$	1,000,000

XML 29 R18.htm IDEA: XBRL DOCUMENT

Warranty Liability (Tables)

9 Months Ended

Mar. 31, 2016

Product Warranties Disclosures [Abstract]

Schedule Of Warranty Liability

Changes in the Company’s warranty liability were approximately as follows:

	Nine Months Ended March 31, 2016			Fiscal Year Ended June 30, 2015
Beginning warranty reserve	$	660,000		$	700,000
Accrual for products sold		130,000			139,000
Expenditures and costs incurred for warranty claims		(120,000	)		(179,000	)
Ending warranty reserve	$	670,000		$	660,000

XML 30 R19.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Tables)

9 Months Ended

Mar. 31, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule Of Stock Compensation Plan Activity

Stock option transactions during the nine months ended March 31, 2016 are summarized as follows:

	Number of Shares			Weighted Average Exercise Price
Outstanding at June 30, 2015		450,800			$2.80
Granted		163,500			$2.05
Exercised		–			–
Cancelled or Forfeited		(14,500	)		$1.80
Outstanding at March 31, 2016		599,800			$2.62

Schedule Of Restricted Stock Awards Activity

Restricted stock transactions during the nine months ended March 31, 2016 are summarized as follows:

	Number of Shares		Weighted Average Grant Date Fair Value
Unvested shares at June 30, 2015		–		–
Granted		53,255		$1.95
Vested		–		–
Forfeited		–		–
Unvested at March 31, 2016		53,255		$1.95

XML 31 R20.htm IDEA: XBRL DOCUMENT

Interim Financial Reporting (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Sales	$ 6,035,700	$ 4,556,977	$ 17,298,995	$ 14,209,239
Common stock equivalents excluded from calculation of diluted earnings per share	159,000	539,900	163,500	609,900
Unamortized debt issuance costs recorded in other non-current assets	$ 21,000		$ 21,000
International [Member]
Sales			$ 591,000	$ 599,000

XML 32 R21.htm IDEA: XBRL DOCUMENT

Inventories (Details) - USD ($)	Mar. 31, 2016	Jun. 30, 2015
Inventory Disclosure [Abstract]
Parts inventory	$ 1,630,000	$ 1,527,000
Work in process	128,000	245,000
Finished goods	723,000	440,000
Less: Reserve for obsolescence	(155,000)	(140,000)
Total	$ 2,325,718	$ 2,072,108

XML 33 R22.htm IDEA: XBRL DOCUMENT

Finite-Life Intangible Assets (Details Narrative) - USD ($)	9 Months Ended	12 Months Ended
	Mar. 31, 2016	Jun. 30, 2015
Finite-Lived Intangible Assets [Line Items]
Accumulated amortization	$ 789,000	$ 698,000
Abandonment [Member]
Finite-Lived Intangible Assets [Line Items]
Abandonment expense of patents	$ 8,000	$ 32,000
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life	15 years
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life	12 years

XML 34 R23.htm IDEA: XBRL DOCUMENT

Finite-Life Intangible Assets (Details) - USD ($)	9 Months Ended		12 Months Ended
Finite-Life Intangible Assets (Details) - USD ($)	Mar. 31, 2016	Mar. 31, 2015	Jun. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Balance, beginning	$ 999,842	$ 1,039,000	$ 1,039,000
Additions	28,000		116,000
Abandonments	(8,000)		(32,000)
Amortization expense	(91,815)	$ (97,931)	(123,000)
Balance, ending	$ 927,931		$ 999,842

XML 35 R24.htm IDEA: XBRL DOCUMENT

Warranty Liability (Details Narrative)	9 Months Ended
Warranty Liability (Details Narrative)	Mar. 31, 2016
Institutional Sales and Sales Outside United States [Member]
Warranty term	3 years

XML 36 R25.htm IDEA: XBRL DOCUMENT

Warranty Liability (Details) - USD ($)	9 Months Ended	12 Months Ended
Warranty Liability (Details) - USD ($)	Mar. 31, 2016	Jun. 30, 2015
Product Warranties Disclosures [Abstract]
Beginning warranty reserve	$ 660,000	$ 700,000
Accrual for products sold	130,000	139,000
Expenditures and costs incurred for warranty claims	(120,000)	(179,000)
Ending warranty reserve	$ 670,000	$ 660,000

XML 37 R26.htm IDEA: XBRL DOCUMENT

Income Taxes (Details Narrative) ) - USD ($)	3 Months Ended		9 Months Ended
Income Taxes (Details Narrative) ) - USD ($)	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Effective tax rate			25.50%
Income tax expense (benefit)	$ 256,000		$ 644,000
Current tax expense (benefit)			938,000
Change in valuation allowance on deferred tax assets		$ (27,000)	(294,000)	$ (358,000)
Income tax benefit - deferred taxes			$ (288,000)

XML 38 R27.htm IDEA: XBRL DOCUMENT

Financing Arrangements (Details Narrative)	9 Months Ended
Financing Arrangements (Details Narrative)	Mar. 31, 2016 USD ($)
Term Loan [Member]
Line of Credit Facility [Line Items]
Principal loan amount	$ 1,210,000
Term loan, interest rate	5.00%
Monthly payments of principal and interest	$ 8,600
Final payment of principal and interest	$ 1,090,000
Term loan maturity date	Dec. 18, 2018
Minimum tangible net worth to be maintained	$ 10,125,000
Venture Bank [Member] \| Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Maximum borrowing capacity	$ 2,500,000
Credit facility effective date	Dec. 18, 2015
Credit facility expiration date	Dec. 18, 2016
Effective interest rate including prime rate	3.50%
Borrowing capacity of eligible accounts receivable	$ 2,500,000
Borrowing capacity of eligible accounts receivable (percent)	57.00%

XML 39 R28.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Details Narrative) - USD ($)	9 Months Ended
Stock-Based Compensation (Details Narrative) - USD ($)	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 153,465	$ 78,596
Unrecognized compensation expense	$ 184,000
Unrecognized compensation expense, period for recognition	1 year 1 month 6 days
Options expired	190,000
Warrants expired	44,100
Employee Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average remaining contractual term	5 years 7 months 17 days
Aggregate intrinsic value	$ 693,000
Options exercisable	389,000
Options exercisable, intrinsic value	$ 220,000
Restricted Stock Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of shares for restricted stock awards	30,000
Fair value of restricted stock awards issued	$ 1.80
Restricted Stock Awards [Member] \| Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	6 months
Issuance of shares for restricted stock awards	23,255
Fair value of restricted stock awards issued	$ 2.15
Restricted Stock Awards [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	1 year
Restricted Stock Awards [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years

XML 40 R29.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Details) - Employee Stock Options [Member]	9 Months Ended
	Mar. 31, 2016 $ / shares shares
Number of Shares
Options outstanding, beginning of year \| shares	450,800
Granted \| shares	163,500
Cancelled or Forfeited \| shares	(14,500)
Options outstanding, end of year \| shares	599,800
Weighted Average Exercise Price
Options outstanding, beginning of year \| $ / shares	$ 2.80
Granted \| $ / shares	2.05
Cancelled or Forfeited \| $ / shares	1.80
Options outstanding, end of year \| $ / shares	$ 2.62

XML 41 R30.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Details 1) - Restricted Stock Awards [Member]	9 Months Ended
	Mar. 31, 2016 $ / shares shares
Number of Shares
Granted \| shares	53,255
Unvested shares, end of year \| shares	53,255
Weighted Average Exercise Price
Granted \| $ / shares	$ 1.95
Unvested shares, end of year \| $ / shares	$ 1.95

EXCEL 42 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 43 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 44 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 46 FilingSummary.xml IDEA: XBRL DOCUMENT 3.4.0.3 html 29 147 1 false 13 0 false 4 false false R1.htm 00000001 - Document - Document And Entity Information Sheet http://electromed.com/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Balance Sheets (Unaudited) Sheet http://electromed.com/role/StatementCondensedBalanceSheets Condensed Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical) Sheet http://electromed.com/role/StatementCondensedBalanceSheetsParenthetical Condensed Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Statements Of Operations (Unaudited) Sheet http://electromed.com/role/StatementCondensedStatementsOfOperations Condensed Statements Of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Statements Of Operations (Unaudited) (Parenthetical) Sheet http://electromed.com/role/StatementCondensedStatementsOfOperationsParenthetical Condensed Statements Of Operations (Unaudited) (Parenthetical) Statements 5 false false R6.htm 00000006 - Statement - Condensed Statements Of Cash Flows (Unaudited) Sheet http://electromed.com/role/StatementCondensedStatementsOfCashFlows Condensed Statements Of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Interim Financial Reporting Sheet http://electromed.com/role/DisclosureInterimFinancialReporting Interim Financial Reporting Notes 7 false false R8.htm 00000008 - Disclosure - Inventories Sheet http://electromed.com/role/DisclosureInventories Inventories Notes 8 false false R9.htm 00000009 - Disclosure - Finite-Life Intangible Assets Sheet http://electromed.com/role/DisclosureFiniteLifeIntangibleAssets Finite-Life Intangible Assets Notes 9 false false R10.htm 00000010 - Disclosure - Warranty Liability Sheet http://electromed.com/role/DisclosureWarrantyLiability Warranty Liability Notes 10 false false R11.htm 00000011 - Disclosure - Income Taxes Sheet http://electromed.com/role/DisclosureIncomeTaxes Income Taxes Notes 11 false false R12.htm 00000012 - Disclosure - Financing Arrangements Sheet http://electromed.com/role/DisclosureFinancingArrangementsAndSubsequentEvent Financing Arrangements Notes 12 false false R13.htm 00000013 - Disclosure - Stock-Based Compensation Sheet http://electromed.com/role/DisclosureStockBasedCompensation Stock-Based Compensation Notes 13 false false R14.htm 00000014 - Disclosure - Commitments And Contingencies Sheet http://electromed.com/role/DisclosureCommitmentsAndContingencies Commitments And Contingencies Notes 14 false false R15.htm 00000015 - Disclosure - Interim Financial Reporting (Policies) Sheet http://electromed.com/role/DisclosureInterimFinancialReportingPolicy Interim Financial Reporting (Policies) Policies 15 false false R16.htm 00000016 - Disclosure - Inventories (Tables) Sheet http://electromed.com/role/DisclosureInventoriesTables Inventories (Tables) Tables http://electromed.com/role/DisclosureInventories 16 false false R17.htm 00000017 - Disclosure - Finite-Life Intangible Assets (Tables) Sheet http://electromed.com/role/DisclosureFiniteLifeIntangibleAssetsTables Finite-Life Intangible Assets (Tables) Tables http://electromed.com/role/DisclosureFiniteLifeIntangibleAssets 17 false false R18.htm 00000018 - Disclosure - Warranty Liability (Tables) Sheet http://electromed.com/role/DisclosureWarrantyLiabilityTables Warranty Liability (Tables) Tables http://electromed.com/role/DisclosureWarrantyLiability 18 false false R19.htm 00000019 - Disclosure - Stock-Based Compensation (Tables) Sheet http://electromed.com/role/DisclosureStockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://electromed.com/role/DisclosureStockBasedCompensation 19 false false R20.htm 00000020 - Disclosure - Interim Financial Reporting (Details Narrative) Sheet http://electromed.com/role/DisclosureInterimFinancialReportingNarrativeDetails Interim Financial Reporting (Details Narrative) Details http://electromed.com/role/DisclosureInterimFinancialReportingPolicy 20 false false R21.htm 00000021 - Disclosure - Inventories (Details) Sheet http://electromed.com/role/DisclosureInventoriesDetails Inventories (Details) Details http://electromed.com/role/DisclosureInventoriesTables 21 false false R22.htm 00000022 - Disclosure - Finite-Life Intangible Assets (Details Narrative) Sheet http://electromed.com/role/DisclosureFiniteLifeIntangibleAssetsNarrativeDetails Finite-Life Intangible Assets (Details Narrative) Details http://electromed.com/role/DisclosureFiniteLifeIntangibleAssetsTables 22 false false R23.htm 00000023 - Disclosure - Finite-Life Intangible Assets (Details) Sheet http://electromed.com/role/DisclosureFiniteLifeIntangibleAssetsScheduleOfFiniteLifeIntangibleAssetsDetails Finite-Life Intangible Assets (Details) Details http://electromed.com/role/DisclosureFiniteLifeIntangibleAssetsTables 23 false false R24.htm 00000024 - Disclosure - Warranty Liability (Details Narrative) Sheet http://electromed.com/role/DisclosureWarrantyLiabilityNarrativeDetails Warranty Liability (Details Narrative) Details http://electromed.com/role/DisclosureWarrantyLiabilityTables 24 false false R25.htm 00000025 - Disclosure - Warranty Liability (Details) Sheet http://electromed.com/role/DisclosureWarrantyLiabilityScheduleOfWarrantyLiabilityDetails Warranty Liability (Details) Details http://electromed.com/role/DisclosureWarrantyLiabilityTables 25 false false R26.htm 00000026 - Disclosure - Income Taxes (Details Narrative) ) Sheet http://electromed.com/role/DisclosureIncomeTaxesNarrativeDetails Income Taxes (Details Narrative) ) Details http://electromed.com/role/DisclosureIncomeTaxes 26 false false R27.htm 00000027 - Disclosure - Financing Arrangements (Details Narrative) Sheet http://electromed.com/role/DisclosureFinancingArrangementsAndSubsequentEventNarrativeDetails Financing Arrangements (Details Narrative) Details http://electromed.com/role/DisclosureFinancingArrangementsAndSubsequentEvent 27 false false R28.htm 00000028 - Disclosure - Stock-Based Compensation (Details Narrative) Sheet http://electromed.com/role/DisclosureStockBasedCompensationNarrativeDetails Stock-Based Compensation (Details Narrative) Details http://electromed.com/role/DisclosureStockBasedCompensationTables 28 false false R29.htm 00000029 - Disclosure - Stock-Based Compensation (Details) Sheet http://electromed.com/role/DisclosureStockBasedCompensationScheduleOfEmployeeOptionActivityDetails Stock-Based Compensation (Details) Details http://electromed.com/role/DisclosureStockBasedCompensationTables 29 false false R30.htm 00000030 - Disclosure - Stock-Based Compensation (Details 1) Sheet http://electromed.com/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockActivityDetails Stock-Based Compensation (Details 1) Details http://electromed.com/role/DisclosureStockBasedCompensationTables 30 false false All Reports Book All Reports elmd-20160331.xml elmd-20160331.xsd elmd-20160331_cal.xml elmd-20160331_def.xml elmd-20160331_lab.xml elmd-20160331_pre.xml true true ZIP 48 0000897101-16-002321-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000897101-16-002321-xbrl.zip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end